AB 907: Coverage for PANDAS and PANS.
- Session Year: 2023-2024
- House: Assembly
- Latest Version Date: 2023-09-18
Current Status:
Failed
(2024-02-12: Consideration of Governor's veto stricken from file.)
Introduced
In Committee
First Chamber
In Committee
Second Chamber
Enacted
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law sets forth specified coverage requirements for health care service plan contracts and health insurance policies, and limits the copayment, coinsurance, deductible, and other cost sharing that may be imposed for specified health care services.
This bill would require a health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2024, to provide coverage for the prophylaxis, diagnosis, and treatment of Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS) and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) that is prescribed or ordered by the treating physician and surgeon. The bill would prohibit coverage for PANDAS and PANS from being subject to a copayment, coinsurance, deductible, or other cost sharing that is greater than that applied to other benefits. The bill would prohibit a plan or insurer from denying or delaying coverage for PANDAS or PANS therapies because the enrollee or insured previously received treatment for PANDAS or PANS or was diagnosed with or received treatment for the condition under a different diagnostic name. Because a willful violation of these provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law sets forth specified coverage requirements for health care service plan contracts and health insurance policies, and limits the copayment, coinsurance, deductible, and other cost sharing that may be imposed for specified health care services.
This bill would require a health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2024, to provide coverage for the prophylaxis, diagnosis, and treatment of Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS) and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) that is prescribed or ordered by the treating physician and surgeon. The bill would prohibit coverage for PANDAS and PANS from being subject to a copayment, coinsurance, deductible, or other cost sharing that is greater than that applied to other benefits. The bill would prohibit a plan or insurer from denying or delaying coverage for PANDAS or PANS therapies because the enrollee or insured previously received treatment for PANDAS or PANS or was diagnosed with or received treatment for the condition under a different diagnostic name. Because a willful violation of these provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law sets forth specified coverage requirements for health care service plan contracts and health insurance policies, and limits the copayment, coinsurance, deductible, and other cost sharing that may be imposed for specified health care services.
This bill would require a health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2024, to provide coverage for the prophylaxis, diagnosis, and treatment of Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS) and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) that is prescribed or ordered by a provider. the treating physician and surgeon. The bill would prohibit coverage for PANDAS and PANS from being subject to a copayment, coinsurance, deductible, or other cost sharing that is greater than that applied to other benefits. The bill would prohibit a plan or insurer from denying or delaying coverage for PANDAS or PANS therapies because the enrollee or insured previously received treatment for PANDAS or PANS or was diagnosed with or received treatment for the condition under a different diagnostic name. Because a willful violation of these provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law sets forth specified coverage requirements for health care service plan contracts and health insurance policies, and limits the copayment, coinsurance, deductible, and other cost sharing that may be imposed for specified health care services.
This bill would require a health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2024, to provide coverage for the prophylaxis, diagnosis, and treatment of Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS) and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) that is prescribed or ordered by a provider. The bill would prohibit coverage for PANDAS and PANS from being subject to a copayment, coinsurance, deductible, or other cost sharing that is greater than that applied to other similar benefits. The bill would prohibit a plan or insurer from denying or delaying coverage for medically necessary treatment of PANDAS or PANS solely therapies because the enrollee or insured previously received treatment for PANDAS or PANS or has been was diagnosed with or received treatment for the condition under a different diagnostic name. Because a willful violation of these provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law sets forth specified coverage requirements for health care service plan contracts and health insurance policies, and limits the copayment, coinsurance, deductible, and other cost sharing that may be imposed for specified health care services.
This bill would require a health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2024, to provide coverage for treatment of Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS) and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) prescribed or ordered by a provider. The bill would prohibit coverage for PANDAS and PANS from being subject to a copayment, coinsurance, deductible, or other cost sharing that is greater than that applied to other similar benefits. The bill would prohibit a plan or insurer from denying or delaying coverage for medically necessary treatment of PANDAS or PANS solely because the enrollee or insured previously received treatment for PANDAS or PANS or has been diagnosed with or received treatment for the condition under a different diagnostic name. Because a willful violation of these provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
(a)A health care service plan contract issued, amended, or renewed on or after January 1, 2024, shall provide coverage for the prophylaxis, diagnosis, and treatment of Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS) and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) that is prescribed or ordered by the treating physician and surgeon. Treatment for PANDAS and PANS that shall be covered includes antibiotics, medication and behavioral therapies to manage neuropsychiatric symptoms, immunomodulating medicines, plasma exchange, and intravenous immunoglobulin therapy.
(b)Coverage for PANDAS and PANS shall not be subject to a copayment, coinsurance, deductible, or other cost sharing that is greater than that applied to other benefits provided by the contract.
(c)(1)Any required authorization for PANDAS and PANS prophylaxis, diagnosis, or treatment shall be provided in a timely manner that is appropriate for the severity of an enrollees condition pursuant to Section 1367.03.
(2)A health care service plan shall not deny or delay coverage for PANDAS or PANS therapies because the enrollee previously received treatment, including the same or similar treatment, for PANDAS or PANS, or because the enrollee was diagnosed with or received treatment for their condition under a different diagnostic name, including autoimmune encephalopathy.
(3)A health care service plan shall not limit coverage of immunomodulating therapies for PANDAS or PANS in a manner that is inconsistent with the treatment recommendations pursuant to subdivision (d), and shall not require a trial of therapies that treat only neuropsychiatric symptoms before authorizing coverage of immunomodulating therapies pursuant to this section.
(d)Coverage for PANDAS and PANS shall adhere to the treatment recommendations developed by a consortium of medical professionals convened to research, identify, and publish clinical practice guidelines and evidence-based standards for the diagnosis and treatment of those disorders.
(e)For billing and diagnostic purposes, PANDAS and PANS shall be coded as autoimmune encephalitis until the American Medical Association and the federal Centers for Medicare and Medicaid Services create and assign a specific code or codes for PANDAS and PANS. After the creation of that code or codes, PANDAS and PANS may be coded as autoimmune encephalitis, PANDAS, or PANS. If PANDAS or PANS is known by a different common name in the future, it may be coded under that name and this section shall apply to that disorder or syndrome.
(f)This section does not apply to a specialized health care service plan contract that covers dental or vision benefits or a Medicare supplement policy.
SEC. 2.Section 10123.38 is added to the Insurance Code, to read:10123.38.(a)A health insurance policy issued, amended, or renewed on or after January 1, 2024, shall provide coverage for the prophylaxis, diagnosis, and treatment of Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS) and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) that is prescribed or ordered by the treating physician and surgeon. Treatment for PANDAS and PANS that shall be covered includes antibiotics, medication and behavioral therapies to manage neuropsychiatric symptoms, immunomodulating medicines, plasma exchange, and intravenous immunoglobulin therapy.
(b)Coverage for PANDAS and PANS shall not be subject to a copayment, coinsurance, deductible, or other cost sharing that is greater than that applied to other benefits provided by the policy.
(c)(1)Any required authorization for PANDAS and PANS prophylaxis, diagnosis, or treatment shall be provided in a timely manner that is appropriate for the severity of an insureds condition pursuant to Section 10133.54.
(2)A health insurer shall not deny or delay coverage for PANDAS or PANS therapies because the insured previously received treatment, including the same or similar treatment, for PANDAS or PANS, or because the insured was diagnosed with or received treatment for their condition under a different diagnostic name, including autoimmune encephalopathy.
(3)A health insurer shall not limit coverage of immunomodulating therapies for PANDAS or PANS in a manner that is inconsistent with the treatment recommendations pursuant to subdivision (d), and shall not require a trial of therapies that treat only neuropsychiatric symptoms before authorizing coverage of immunomodulating therapies pursuant to this section.
(d)Coverage for PANDAS and PANS shall adhere to the treatment recommendations developed by a consortium of medical professionals convened to research, identify, and publish clinical practice guidelines and evidence-based standards for the diagnosis and treatment of those disorders.
(e)For billing and diagnostic purposes, PANDAS and PANS shall be coded as autoimmune encephalitis until the American Medical Association and the federal Centers for Medicare and Medicaid Services create and assign a specific code or codes for PANDAS and PANS. After the creation of that code or codes, PANDAS and PANS may be coded as autoimmune encephalitis, PANDAS, or PANS. If PANDAS or PANS is known by a different common name in the future, it may be coded under that name and this section shall apply to that disorder or syndrome.
(f)This section does not apply to a specialized health insurance policy that covers dental or vision benefits or a Medicare supplement policy.
SEC. 3.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)A health care service plan contract issued, amended, or renewed on or after January 1, 2024, shall provide coverage for the prophylaxis, diagnosis, and treatment of Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS) and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) that is prescribed or ordered by the treating physician and surgeon. Treatment for PANDAS and PANS that shall be covered includes antibiotics, medication and behavioral therapies to manage neuropsychiatric symptoms, immunomodulating medicines, plasma exchange, and intravenous immunoglobulin therapy.
(b)Coverage for PANDAS and PANS shall not be subject to a copayment, coinsurance, deductible, or other cost sharing that is greater than that applied to other benefits provided by the contract.
(c)(1)Any required authorization for PANDAS and PANS prophylaxis, diagnosis, or treatment shall be provided in a timely manner that is appropriate for the severity of an enrollees condition pursuant to Section 1367.03.
(2)A health care service plan shall not deny or delay coverage for PANDAS or PANS therapies because the enrollee previously received treatment, including the same or similar treatment, for PANDAS or PANS, or because the enrollee was diagnosed with or received treatment for their condition under a different diagnostic name, including autoimmune encephalopathy.
(3)A health care service plan shall not limit coverage of immunomodulating therapies for PANDAS or PANS in a manner that is inconsistent with the treatment recommendations pursuant to subdivision (d), and shall not require a trial of therapies that treat only neuropsychiatric symptoms before authorizing coverage of immunomodulating therapies pursuant to this section.
(d)Coverage for PANDAS and PANS shall adhere to the treatment recommendations developed by a consortium of medical professionals convened to research, identify, and publish clinical practice guidelines and evidence-based standards for the diagnosis and treatment of those disorders.
(e)For billing and diagnostic purposes, PANDAS and PANS shall be coded as autoimmune encephalitis until the American Medical Association and the federal Centers for Medicare and Medicaid Services create and assign a specific code or codes for PANDAS and PANS. After the creation of that code or codes, PANDAS and PANS may be coded as autoimmune encephalitis, PANDAS, or PANS. If PANDAS or PANS is known by a different common name in the future, it may be coded under that name and this section shall apply to that disorder or syndrome.
(f)This section does not apply to a specialized health care service plan contract that does not cover an essential health benefit, as defined in Section 1367.005, covers dental or vision benefits or a Medicare supplement policy.
SEC. 2.Section 10123.38 is added to the Insurance Code, to read:10123.38.(a)A health insurance policy issued, amended, or renewed on or after January 1, 2024, shall provide coverage for the prophylaxis, diagnosis, and treatment of Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS) and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) that is prescribed or ordered by the treating physician and surgeon. Treatment for PANDAS and PANS that shall be covered includes antibiotics, medication and behavioral therapies to manage neuropsychiatric symptoms, immunomodulating medicines, plasma exchange, and intravenous immunoglobulin therapy.
(b)Coverage for PANDAS and PANS shall not be subject to a copayment, coinsurance, deductible, or other cost sharing that is greater than that applied to other benefits provided by the policy.
(c)(1)Any required authorization for PANDAS and PANS prophylaxis, diagnosis, or treatment shall be provided in a timely manner that is appropriate for the severity of an insureds condition pursuant to Section 10133.54.
(2)A health insurer shall not deny or delay coverage for PANDAS or PANS therapies because the insured previously received treatment, including the same or similar treatment, for PANDAS or PANS, or because the insured was diagnosed with or received treatment for their condition under a different diagnostic name, including autoimmune encephalopathy.
(3)A health insurer shall not limit coverage of immunomodulating therapies for PANDAS or PANS in a manner that is inconsistent with the treatment recommendations pursuant to subdivision (d), and shall not require a trial of therapies that treat only neuropsychiatric symptoms before authorizing coverage of immunomodulating therapies pursuant to this section.
(d)Coverage for PANDAS and PANS shall adhere to the treatment recommendations developed by a consortium of medical professionals convened to research, identify, and publish clinical practice guidelines and evidence-based standards for the diagnosis and treatment of those disorders.
(e)For billing and diagnostic purposes, PANDAS and PANS shall be coded as autoimmune encephalitis until the American Medical Association and the federal Centers for Medicare and Medicaid Services create and assign a specific code or codes for PANDAS and PANS. After the creation of that code or codes, PANDAS and PANS may be coded as autoimmune encephalitis, PANDAS, or PANS. If PANDAS or PANS is known by a different common name in the future, it may be coded under that name and this section shall apply to that disorder or syndrome.
(f)This section does not apply to a specialized health insurance policy that does not cover an essential health benefit, as defined in Section 10112.27, covers dental or vision benefits or a Medicare supplement policy.
SEC. 3.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)A health care service plan contract issued, amended, or renewed on or after January 1, 2024, shall provide coverage for the prophylaxis, diagnosis, and treatment of Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS) and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) that is prescribed or ordered by a provider. the treating physician and surgeon. Treatment for PANDAS and PANS that shall be covered includes antibiotics, medication and behavioral therapies to manage neuropsychiatric symptoms, immunomodulating medicines, plasma exchange, and intravenous immunoglobulin therapy.
(b)Coverage for PANDAS and PANS shall not be subject to a copayment, coinsurance, deductible, or other cost sharing that is greater than that applied to other benefits provided by the contract.
(c)(1)Any required authorization for PANDAS and PANS prophylaxis, diagnosis, or treatment shall be provided in a timely manner that is appropriate for the severity of an enrollees condition pursuant to Section 1367.03.
(2)A health care service plan shall not deny or delay coverage for PANDAS or PANS therapies because the enrollee previously received treatment, including the same or similar treatment, for PANDAS or PANS, or because the enrollee was diagnosed with or received treatment for their condition under a different diagnostic name, including autoimmune encephalopathy.
(3)A health care service plan shall not limit coverage of immunomodulating therapies for PANDAS or PANS in a manner that is inconsistent with the treatment recommendations pursuant to subdivision (d), and shall not require a trial of therapies that treat only neuropsychiatric symptoms before authorizing coverage of immunomodulating therapies pursuant to this section.
(d)Coverage for PANDAS and PANS shall adhere to the treatment recommendations developed by a consortium of medical professionals convened to research, identify, and publish clinical practice guidelines and evidence-based standards for the diagnosis and treatment of those disorders.
(e)For billing and diagnostic purposes, PANDAS and PANS shall be coded as autoimmune encephalitis until the American Medical Association and the federal Centers for Medicare and Medicaid Services create and assign a specific code or codes for PANDAS and PANS. After the creation of that code or codes, PANDAS and PANS may be coded as autoimmune encephalitis, PANDAS, or PANS. If PANDAS or PANS is known by a different common name in the future, it may be coded under that name and this section shall apply to that disorder or syndrome.
(f)This section does not apply to a specialized health care service plan contract that does not cover an essential health benefit, as defined in Section 1367.005, or a Medicare supplement policy.
SEC. 2.Section 10123.38 is added to the Insurance Code, to read:10123.38.(a)A health insurance policy issued, amended, or renewed on or after January 1, 2024, shall provide coverage for the prophylaxis, diagnosis, and treatment of Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS) and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) that is prescribed or ordered by a provider. the treating physician and surgeon. Treatment for PANDAS and PANS that shall be covered includes antibiotics, medication and behavioral therapies to manage neuropsychiatric symptoms, immunomodulating medicines, plasma exchange, and intravenous immunoglobulin therapy.
(b)Coverage for PANDAS and PANS shall not be subject to a copayment, coinsurance, deductible, or other cost sharing that is greater than that applied to other benefits provided by the policy.
(c)(1)Any required authorization for PANDAS and PANS prophylaxis, diagnosis, or treatment shall be provided in a timely manner that is appropriate for the severity of an insureds condition pursuant to Section 10133.54.
(2)A health insurer shall not deny or delay coverage for PANDAS or PANS therapies because the insured previously received treatment, including the same or similar treatment, for PANDAS or PANS, or because the insured was diagnosed with or received treatment for their condition under a different diagnostic name, including autoimmune encephalopathy.
(3)A health insurer shall not limit coverage of immunomodulating therapies for PANDAS or PANS in a manner that is inconsistent with the treatment recommendations pursuant to subdivision (d), and shall not require a trial of therapies that treat only neuropsychiatric symptoms before authorizing coverage of immunomodulating therapies pursuant to this section.
(d)Coverage for PANDAS and PANS shall adhere to the treatment recommendations developed by a consortium of medical professionals convened to research, identify, and publish clinical practice guidelines and evidence-based standards for the diagnosis and treatment of those disorders.
(e)For billing and diagnostic purposes, PANDAS and PANS shall be coded as autoimmune encephalitis until the American Medical Association and the federal Centers for Medicare and Medicaid Services create and assign a specific code or codes for PANDAS and PANS. After the creation of that code or codes, PANDAS and PANS may be coded as autoimmune encephalitis, PANDAS, or PANS. If PANDAS or PANS is known by a different common name in the future, it may be coded under that name and this section shall apply to that disorder or syndrome.
(f)This section does not apply to a specialized health insurance policy that does not cover an essential health benefit, as defined in Section 10112.27, or a Medicare supplement policy.
SEC. 3.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)A health care service plan contract issued, amended, or renewed on or after January 1, 2024, shall provide coverage for the prophylaxis, diagnosis, and treatment of Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS) and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) that is prescribed or ordered by a provider. Treatment for PANDAS and PANS that shall be covered includes antibiotics, medication and behavioral therapies to manage neuropsychiatric symptoms, immunomodulating medicines, plasma exchange, and intravenous immunoglobulin therapy.
(b)Coverage for PANDAS and PANS shall not be subject to a copayment, coinsurance, deductible, or other cost sharing that is greater than that applied to other similar benefits provided by the contract.
(c)(1)Coverage Any required authorization for PANDAS and PANS prophylaxis, diagnosis, or treatment shall be provided in a timely manner that is appropriate for the severity of an enrollees condition pursuant to Section 1367.03.
(2)A health care service plan shall not deny or delay coverage for medically necessary treatment of PANDAS or PANS solely therapies because the enrollee previously received treatment, including the same or similar treatment, for PANDAS or PANS PANS, or because the enrollee has been was diagnosed with or received treatment for their condition under a different diagnostic name, including autoimmune encephalopathy.
(3)Coverage for any form of medically necessary treatment shall not be limited over a lifetime of an enrollee or by contract period.(4)This section does not prohibit a plan from requesting treatment notes and anticipated duration of treatment and outcomes from a provider.(3)A health care service plan shall not limit coverage of immunomodulating therapies for PANDAS or PANS in a manner that is inconsistent with the treatment recommendations pursuant to subdivision (d), and shall not require a trial of therapies that treat only neuropsychiatric symptoms before authorizing coverage of immunomodulating therapies pursuant to this section.
(d)Coverage for PANDAS and PANS shall adhere to the treatment recommendations developed by a consortium of medical professionals convened to research, identify, and publish best practice clinical practice guidelines and evidence-based standards for the diagnosis and treatment of those disorders that are accessible to providers and are based on evidence of positive patient outcomes. disorders.
(e)For billing and diagnostic purposes, PANDAS and PANS shall be coded as autoimmune encephalitis until the American Medical Association and the federal Centers for Medicare and Medicaid Services create and assign a specific code or codes for PANDAS and PANS. After the creation of that code or codes, PANDAS and PANS may be coded as autoimmune encephalitis, PANDAS, or PANS. If PANDAS or PANS is known by a different common name in the future, it may be coded under that name and this section shall apply to that disorder or syndrome.
(f)This section does not apply to a specialized health care service plan contract that does not cover an essential health benefit, as defined in Section 1367.005, or a Medicare supplement policy.
SEC. 2.Section 10123.38 is added to the Insurance Code, to read:10123.38.(a)A health insurance policy issued, amended, or renewed on or after January 1, 2024, shall provide coverage for the prophylaxis, diagnosis, and treatment of Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS) and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) that is prescribed or ordered by a provider. Treatment for PANDAS and PANS that shall be covered includes antibiotics, medication and behavioral therapies to manage neuropsychiatric symptoms, immunomodulating medicines, plasma exchange, and intravenous immunoglobulin therapy.
(b)Coverage for PANDAS and PANS shall not be subject to a copayment, coinsurance, deductible, or other cost sharing that is greater than that applied to other similar benefits provided by the policy.
(c)(1)Coverage Any required authorization for PANDAS and PANS prophylaxis, diagnosis, or treatment shall be provided in a timely manner that is appropriate for the severity of an insureds condition pursuant to Section 10133.54.
(2)A health insurer shall not deny or delay coverage for medically necessary treatment of PANDAS or PANS solely therapies because the insured previously received treatment, including the same or similar treatment, for PANDAS or PANS PANS, or because the insured has been was diagnosed with or received treatment for their condition under a different diagnostic name, including autoimmune encephalopathy.
(3)Coverage for any form of medically necessary treatment shall not be limited over a lifetime of an insured or by policy period.(4)This section does not prohibit an insurer from requesting treatment notes and anticipated duration of treatment and outcomes from a provider.(3)A health insurer shall not limit coverage of immunomodulating therapies for PANDAS or PANS in a manner that is inconsistent with the treatment recommendations pursuant to subdivision (d), and shall not require a trial of therapies that treat only neuropsychiatric symptoms before authorizing coverage of immunomodulating therapies pursuant to this section.
(d)Coverage for PANDAS and PANS shall adhere to the treatment recommendations developed by a consortium of medical professionals convened to research, identify, and publish best practice clinical practice guidelines and evidence-based standards for the diagnosis and treatment of those disorders that are accessible to providers and are based on evidence of positive patient outcomes. disorders.
(e)For billing and diagnostic purposes, PANDAS and PANS shall be coded as autoimmune encephalitis until the American Medical Association and the federal Centers for Medicare and Medicaid Services create and assign a specific code or codes for PANDAS and PANS. After the creation of that code or codes, PANDAS and PANS may be coded as autoimmune encephalitis, PANDAS, or PANS. If PANDAS or PANS is known by a different common name in the future, it may be coded under that name and this section shall apply to that disorder or syndrome.
(f)This section does not apply to a specialized health insurance policy that does not cover an essential health benefit, as defined in Section 10112.27, or a Medicare supplement policy.
SEC. 3.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)A health care service plan contract issued, amended, or renewed on or after January 1, 2024, shall provide coverage for treatment of Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS) and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) prescribed or ordered by a provider. Treatment for PANDAS and PANS that shall be covered includes antibiotics, medication and behavioral therapies to manage neuropsychiatric symptoms, immunomodulating medicines, plasma exchange, and intravenous immunoglobulin therapy.
(b)Coverage for PANDAS and PANS shall not be subject to a copayment, coinsurance, deductible, or other cost sharing that is greater than that applied to other similar benefits provided by the contract.
(c)(1)Coverage for PANDAS and PANS shall be provided in a timely manner pursuant to Section 1367.03.
(2)A health care service plan shall not deny or delay coverage for medically necessary treatment of PANDAS or PANS solely because the enrollee previously received treatment, including the same or similar treatment, for PANDAS or PANS or because the enrollee has been diagnosed with or received treatment for their condition under a different diagnostic name, including autoimmune encephalopathy.
(3)Coverage for any form of medically necessary treatment shall not be limited over a lifetime of an enrollee or by contract period.
(4)This section does not prohibit a plan from requesting treatment notes and anticipated duration of treatment and outcomes from a provider.
(d)Coverage for PANDAS and PANS shall adhere to the treatment recommendations developed by a consortium of medical professionals convened to research, identify, and publish best practice standards for the diagnosis and treatment of those disorders that are accessible to providers and are based on evidence of positive patient outcomes.
(e)For billing and diagnostic purposes, PANDAS and PANS shall be coded as autoimmune encephalitis until the American Medical Association and the federal Centers for Medicare and Medicaid Services create and assign a specific code or codes for PANDAS and PANS. After the creation of that code or codes, PANDAS and PANS may be coded as autoimmune encephalitis, PANDAS, or PANS. If PANDAS or PANS is known by a different common name in the future, it may be coded under that name and this section shall apply to that disorder or syndrome.
SEC. 2.Section 10123.38 is added to the Insurance Code, to read:10123.38.(a)A health insurance policy issued, amended, or renewed on or after January 1, 2024, shall provide coverage for treatment of Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS) and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) prescribed or ordered by a provider. Treatment for PANDAS and PANS that shall be covered includes antibiotics, medication and behavioral therapies to manage neuropsychiatric symptoms, immunomodulating medicines, plasma exchange, and intravenous immunoglobulin therapy.
(b)Coverage for PANDAS and PANS shall not be subject to a copayment, coinsurance, deductible, or other cost sharing that is greater than that applied to other similar benefits provided by the policy.
(c)(1)Coverage for PANDAS and PANS shall be provided in a timely manner pursuant to Section 10133.54.
(2)A health insurer shall not deny or delay coverage for medically necessary treatment of PANDAS or PANS solely because the insured previously received treatment, including the same or similar treatment, for PANDAS or PANS or because the insured has been diagnosed with or received treatment for their condition under a different diagnostic name, including autoimmune encephalopathy.
(3)Coverage for any form of medically necessary treatment shall not be limited over a lifetime of an insured or by policy period.
(4)This section does not prohibit an insurer from requesting treatment notes and anticipated duration of treatment and outcomes from a provider.
(d)Coverage for PANDAS and PANS shall adhere to the treatment recommendations developed by a consortium of medical professionals convened to research, identify, and publish best practice standards for the diagnosis and treatment of those disorders that are accessible to providers and are based on evidence of positive patient outcomes.
(e)For billing and diagnostic purposes, PANDAS and PANS shall be coded as autoimmune encephalitis until the American Medical Association and the federal Centers for Medicare and Medicaid Services create and assign a specific code or codes for PANDAS and PANS. After the creation of that code or codes, PANDAS and PANS may be coded as autoimmune encephalitis, PANDAS, or PANS. If PANDAS or PANS is known by a different common name in the future, it may be coded under that name and this section shall apply to that disorder or syndrome.
SEC. 3.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
|
Date
|
Status
|
|---|---|
| Feb 12, 2024 | Consideration of Governor's veto stricken from file. |
| Jan 3, 2024 | Consideration of Governor's veto pending. |
| Oct 7, 2023 | Vetoed by Governor. |
| Sep 21, 2023 | Enrolled and presented to the Governor at 3:30 p.m. |
| Sep 13, 2023 | Senate amendments concurred in. To Engrossing and Enrolling. (Ayes 69. Noes 0. Page 3366.). |
| Sep 12, 2023 | In Assembly. Concurrence in Senate amendments pending. |
| Sep 12, 2023 | Read third time. Passed. Ordered to the Assembly. (Ayes 33. Noes 0. Page 2619.). |
| Sep 5, 2023 | Read second time. Ordered to third reading. |
| Sep 1, 2023 | From committee: Do pass. (Ayes 5. Noes 0.) (September 1). |
| Jul 10, 2023 | In committee: Referred to APPR. suspense file. |
| Jul 3, 2023 | Read second time and amended. Re-referred to Com. on APPR. |
| Jun 29, 2023 | From committee: Amend, and do pass as amended and re-refer to Com. on APPR. (Ayes 11. Noes 0.) (June 28). |
| Jun 15, 2023 | From committee chair, with author's amendments: Amend, and re-refer to committee. Read second time, amended, and re-referred to Com. on HEALTH. |
| Jun 14, 2023 | Referred to Com. on HEALTH. |
| Jun 1, 2023 | In Senate. Read first time. To Com. on RLS. for assignment. |
| May 31, 2023 | Read third time. Passed. Ordered to the Senate. (Ayes 69. Noes 0. Page 2051.) |
| May 18, 2023 | Read second time. Ordered to third reading. |
| May 18, 2023 | From committee: Do pass. (Ayes 12. Noes 1.) (May 18). |
| May 10, 2023 | In committee: Set, first hearing. Referred to APPR. suspense file. |
| Apr 26, 2023 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 11. Noes 0.) (April 25). Re-referred to Com. on APPR. |
| Mar 20, 2023 | Re-referred to Com. on HEALTH. |
| Mar 16, 2023 | From committee chair, with author's amendments: Amend, and re-refer to Com. on HEALTH. Read second time and amended. |
| Feb 23, 2023 | Referred to Com. on HEALTH. |
| Feb 15, 2023 | From printer. May be heard in committee March 17. |
| Feb 14, 2023 | Read first time. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Sep 13, 2023 | AB 907 Lowenthal Concurrence in Senate Amendments | Assembly Floor |
Passed |
|
| Sep 12, 2023 | Assembly 3rd Reading AB907 Lowenthal By Gonzalez | Senate Floor |
Passed |
|
| Sep 1, 2023 | Do pass | Senate Standing Committee on Appropriations |
Passed |
|
| Jul 10, 2023 | Placed on suspense file | Senate Standing Committee on Appropriations |
Passed |
|
| Jun 28, 2023 | Do pass as amended, but first amend, and re-refer to the Committee on [Appropriations] | Senate Standing Committee on Health |
Passed |
|
| May 31, 2023 | AB 907 Lowenthal Assembly Third Reading | Assembly Floor |
Passed |
|
| May 18, 2023 | Do pass. | Assembly Standing Committee on Appropriations |
Passed |
|
| Apr 25, 2023 | Do pass and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Health |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
|
Organization
|
Position
|
Date
|
|---|---|---|
| Alliance to Solve PANS & Immune-Related Encephalopathies | ** Support | |
| America'S Health Insurance Plans | ** Against | |
| Association Of California Life & Health Insurance Companies | ** Against | |
| Autoimmune Registry | ** Support | |
| California Association Of Health Plans | ** Against | |
| California ChildrenS Hospital Association | ** Support | |
| California Coalition for PANS/PANDAS Advocacy | ** Support | |
| California Federation of Teachers, AFL-CIO | ** Support | |
| California Health Coalition Advocacy | ** Support | |
| California Life Sciences | ** Support | |
| California School Nurses Organization | ** Support | |
| California Teamsters Public Affairs Council | ** Support | |
| Department Of Finance | ** Against | |
| Expand, the European Immuno-neuropsychiatric Association | ** Support | |
| International Longshore and Warehouse Union | ** Support | |
| Memorial Care Health System | ** Support | |
| Moleculera Labs | ** Support | |
| Northwest PANDAS/PANS Network | ** Support | |
| Numerous individuals | ** Support | |
| PANDAS Physician Network | ** Support | |
| PANDAS Physicians Network, a Division of The Foundation for Brain Science and Immunology | ** Support | |
| SAG-AFTRA | ** Support | |
| Several individuals | ** Support | |
| Stand Up Sacramento County | ** Support | |
| The Alex Manfull Fund | ** Support | |
| The European Immuno-neuropsychiatric Association | ** Support | |
| The Pace Foundation | ** Support | |
| Virginia Alliance for Pans Pandas Action | ** Support |
GOVERNOR'S VETO
GV Bill Id:AB 907
Author:(Lowenthal)
As Enrolled Ver:September 18, 2023
2/3 vote
SUMMARY
Requires a health care service plan (health plan) contract or health insurance policy to provide coverage for the prophylaxis, diagnosis, and treatment of Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS) and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) that is prescribed or ordered by the treating physician and surgeon. Prohibits coverage for PANDAS and PANS from being subject to a copayment, coinsurance, deductible, or other cost sharing that is greater than that applied to other benefits. Prohibits a plan or insurer from denying or delaying coverage for PANDAS or PANS therapies because the enrollee or insured previously received treatment for PANDAS or PANS or was diagnosed with or received treatment for the condition under a different diagnostic name
Senate Amendments
Clarify that the requirement for coverage of PANDAS and PANS is as prescribed or ordered by the treating physician and surgeon (rather than provider).
Governor’s Veto Message
This bill would require health plans to cover specific prophylaxis, diagnosis, and treatment of PANDAS and PANS with limited cost sharing.
While I support the author's goal of ensuring that children with PANS and PANDAS receive the treatment they need in a timely manner, this bill creates a disease-specific mandate and contains provisions that would be duplicative of existing laws for timely access standards and grievance processes through the Department of Managed Health Care (DMHC) and Department of Insurance (CDI). Further, this bill removes the medical necessity requirement, which is a standard condition for health plans in determining coverage of specific services.
COMMENTS
According to the California Health Benefits Review Program (CHBRP), PANDAS/PANS are terms used to describe a subset of children with symptoms that include a sudden onset of a collection of neuropsychiatric symptoms co-occurring with obsessive-compulsive disorder (OCD) and/or tic disorders usually following an infection. PANDAS, currently classified as a subset of PANS, is hypothesized by some to be triggered by an autoimmune response to Group A Streptococcal (Strep) bacteria (which cause Strep throat or soft tissue infections).
Prevalence. PANDAS/PANS has been primarily described in children between the ages of three and 12 years; however, the exact prevalence and age distribution of PANDAS/PANS is unknown. Because OCD is a required symptom for the diagnosis of PANDAS and PANS, it is thought their prevalence can be estimated as a subset of the prevalence of pediatric OCD. Epidemiological research estimates that 0.5% to 5% of children in the United States are affected by OCD. PANDAS/PANS is uncommon and despite the first publication on the topic occurring in 1998, it remains unfamiliar to much of the clinical community. Clinicians commonly involved in diagnosing PANDAS/PANS may include a family physician, pediatrician, pediatric nurse practitioner, pediatric neurologist, pediatric psychiatrist, neurodevelopmental pediatrician, pediatric rheumatologist, and pediatric allergist/immunologist. Despite the wide variety of clinicians listed, many are unfamiliar with the syndromes and how to diagnose or treat them. There are 10 PANDAS/PANS clinics nationwide with two located in California (Stanford and University of California, Los Angeles (UCLA)). Due to the lack of diagnostic laboratory or imaging tests specific to PANDAS/PANS, and the overlap of symptoms with multiple conditions, the diagnostic process for these syndromes is challenging.
Barriers. Barriers for the diagnosis and treatment of PANDAS/PANS include the lack of evidence on effective treatment options. The lack of clinicians familiar with PANDAS and PANS contributes to long distance travel (and associated travel expenses) for families seeking care. PANDAS/PANS symptoms overlap with symptoms of other conditions, thus the lack of a definitive test and reliance on a differential diagnosis can lead to delayed diagnosis. Misdiagnosis, and children's suppression of behaviors during assessments are also treatment barriers in PANDAS/PANS. Treatment for moderate-to-severe PANDAS/PANS generally requires pediatric specialists, and ideally, coordinated care among treating clinicians who may be in different care settings. For patients with mild or moderate cases, weekly therapy with Cognitive Behavioral Therapy (CBT), or outpatient daily therapy may be prescribed, but due to pediatric behavioral health workforce shortages in California, both may be difficult to access. For patients with more severe cases, space in inpatient day programs or hospitalizations, where treatment may last from one week to months, may be difficult to obtain due to California's shortage of pediatric psychiatric care clinicians and inpatient and treatment beds.
CHBRP analysis. CHBRP reviewed this bill and states the following in its analysis:
- Impact on expenditures. This bill increases total net annual expenditures by total net annual $2,990,000 or total net annual 0.0020% for enrollees with DMHC-regulated plans (including DMHC-regulated Medi-Cal) and CDI-regulated policies. Premiums for enrollees in individual plans purchased through Covered California would increase by a total of $69,000 in annual expenditures.
- Medi-Cal. For this analysis, CHBRP has included potential impacts on Medi-Cal beneficiaries. In addition to the expected increase of $1.47 million in premiums, CHBRP is estimating for the 8.8 million Medi-Cal beneficiaries enrolled in DMHC-regulated plans (a figure that represents a 0.005% increase in premiums), it seems reasonable to assume that a population proportional increase of $370,000 would occur for the 2.0 million beneficiaries enrolled in county organized health systems (COHS) managed care.
- CalPERS. For enrollees associated with CalPERS in DMHC-regulated plans, premiums would increase by 0.001% ($0.01 per member per month, or $83,000 total increase in expenditures).
- Medical effectiveness. CHBRP analyzed the strength of evidence for the effectiveness of antibiotics, psychotropic medications, cognitive behavioral therapy, plasma exchange, IVIg and other immunomodulating medications addressed by this bill, specifically, for children affected by PANDAS/PANS. Overall, the evidence is insufficient or inconclusive that any of these treatments are effective at reducing prominent symptoms, such as OCD symptoms, tics, or eating restrictions, for pediatric patients with PANDAS/PANS. The body of research on PANDAS and PANS is small (number of studies and sample sizes of available studies) compared with many other diseases and conditions. Additional studies involving controlled clinical trials, larger sample sizes, and clear eligibility criteria are necessary to determine which treatments are effective for children with PANDAS/PANS. More specifically, CHBRP found insufficient evidence on the effectiveness of CBT, psychotropics, Non-steroidal anti-inflammatory drugs, corticosteroids, plasma exchange, rituximab, mycophenolate mofetil, and vitamin D in reducing or eliminating the prominent symptoms associated with PANDAS/PANS. CHBRP found inconclusive evidence on the effectiveness of antibiotics and IVIg in reducing or eliminating the prominent symptoms associated with PANDAS/PANS. Each of the medications reviewed for this analysis is associated with a variety of side effects and harms.
According to the Author
Despite published PANDAS/PANS treatment guidelines that established the standard of care in 2017, insurers have continued to adhere to their own policy statements forbidding authorization of immune-focused treatments like IVIg. As a result, treatments are denied routinely without real consideration. When a prescriber or family appeals, insurers typically uphold their denial, claiming "lack of medical necessity," or "treatment is experimental." Reviewers working for insurers are often nurses or pharmacists, not physicians, and even when an insurer engages the service of a physician to determine authorization, the physician reviewer generally lacks experience in this complex, uncommon, and devastating disorder. A typical delay in receiving IVIg due to insurance denials is measured in months, if not years. Many families give up. Meanwhile, most PANS/PANDAS sufferers cannot attend school or require intensive academic accommodations such as home hospital school. They may be hospitalized medically or psychiatrically, resulting in more cost and unnecessary suffering. They may accumulate permanent neurological damage. Their parents are often unable to work and may require state unemployment or family medical leave benefits. The author states children lucky enough to have parents with financial resources to pay out of pocket, or the savvy and persistence necessary to battle the protracted appeals process, recover well with appropriate treatment. Families who lack these resources endure financial ruin, possible child abuse allegations, police "wellness checks" that go awry, and even successful suicides. According to the author, this last sad fact has led to the establishment of the POND Brain Bank at Georgetown University, where the brains of three deceased young PANDAS/PANS patients are now contributing to scientific knowledge. Ten states have passed legislation similar to this bill since 2017, including two thus far in 2023. Without legislation, insurers have shown no willingness to grant timely and medically indicated treatment to PANS/PANDAS children. As a result, the author concludes that families continue to suffer unnecessarily and the state continues to incur costs related to special education and parental loss of employment and productivity.
Arguments in Support
PANDAS Physicians Network (PPN) is non-profit organization that maintains the industry standard PPN Guidelines for Diagnostics and Therapeutics, fosters continuous education and communication within the multi-disciplinary medical community and sponsors research for developing diagnostic tests, treatment protocols, and ultimately a cure for PANS and PANDAS. With PANS/PANDAS, an infection triggers a misdirected immune response causing inflammation in the brain. Psychiatric and neurologic symptoms manifest due to the inflammation. The hallmark trait of PANS/PANDAS is the abrupt and severe onset of OCD and/or severe eating restrictions. These primary symptoms are accompanied by other emotional and behavioral changes, frequent urination, tics, motor abnormalities and/or handwriting changes. PANS and PANDAS are treatable. Early intervention and treatment are keys to easing suffering, significantly improving mental health, shortening the duration of the illness, and laying the foundation for a long-term full recovery. Lack of treatment may lead to ongoing, worsening psychological distress, school and family disruption, psychiatric hospitalization, dramatic weight loss resulting in the need for a feeding tube or intravenous hydration, and/or an evolution of the illness into a chronic state. In severe cases, PANS/PANDAS children have lost their lives to suicide. This is preventable.
Arguments in Opposition
The California Association of Health Plans, the Association of California Life and Health Insurance Companies, and America's Health Insurance Plans write that state mandates increase costs of coverage, especially for families who buy coverage without subsidies, small business owners who cannot or do not wish to self-insure, and California taxpayers who foot the bill for the state's share of those mandates. Health plans compete for business based on innovative benefit designs that increase access to care, improve quality, and contain costs. The opposition states mandate will increase costs and limit flexibility for employers. Faced with higher costs, employers must make difficult decisions about whether to absorb premium increases or seek alternative coverage options. The Department of Finance is opposed to this bill, as it creates new costs and pressures to the Managed Care Fund not included in the 2023-24 budget plan. DMHC notes concerns that as drafted, this bill may be difficult to interpret and enforce. Additionally, the Department believes this type of disease-specific statute could create disparities and inequities for individuals that experience other health conditions, while increasing health care costs for all enrollees. The CHBRP analysis notes concerns with the medical effectiveness of treatments addressed by this bill. The analysis noted either insufficient or inconclusive evidence that any of the treatments included in this bill are effective at reducing prominent symptoms for pediatric patients with PANDAS/PANS.
FISCAL COMMENTS
According to the Senate Appropriations Committee:
- DMHC estimates costs to be approximately $157,000 in fiscal year (FY) 2023-24, $990,000 in FY 2024-25, and $1,014,000 in FY 2025-26 and annually thereafter for state operations (Managed Care Fund).
- CDI estimates costs of $7,000 in FY 2023-24 for state operations (Insurance Fund).
- Unknown, ongoing costs, likely low millions, for the Medi-Cal program to provide the services (General Fund and federal funds).
VOTES
ASM HEALTH: 11-0-4
YES: Wood, Waldron, Aguiar-Curry, Boerner, Wendy Carrillo, Maienschein, McCarty, Rodriguez, Santiago, Villapudua, Weber
ABS, ABST OR NV: Arambula, Flora, Vince Fong, Joe Patterson
ASM APPROPRIATIONS: 12-1-3
YES: Holden, Bryan, Calderon, Wendy Carrillo, Mike Fong, Hart, Lowenthal, Mathis, Papan, Pellerin, Weber, Ortega
NO: Dixon
ABS, ABST OR NV: Megan Dahle, Robert Rivas, Sanchez
ASSEMBLY FLOOR: 69-0-11
YES: Addis, Aguiar-Curry, Alvarez, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Juan Carrillo, Wendy Carrillo, Cervantes, Connolly, Megan Dahle, Essayli, Mike Fong, Friedman, Gabriel, Gallagher, Garcia, Gipson, Grayson, Haney, Hart, Holden, Hoover, Irwin, Jackson, Jones-Sawyer, Kalra, Lee, Low, Lowenthal, Maienschein, Mathis, McCarty, McKinnor, Muratsuchi, Stephanie Nguyen, Ortega, Pacheco, Papan, Pellerin, Petrie‑Norris, Quirk-Silva, Ramos, Reyes, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Santiago, Schiavo, Soria, Ta, Ting, Valencia, Villapudua, Waldron, Wallis, Ward, Weber, Wicks, Wilson, Wood, Zbur, Rendon
ABS, ABST OR NV: Alanis, Arambula, Chen, Davies, Dixon, Flora, Vince Fong, Lackey, Jim Patterson, Joe Patterson, Sanchez
SENATE FLOOR: 33-0-7
YES: Allen, Alvarado-Gil, Archuleta, Ashby, Atkins, Becker, Blakespear, Bradford, Cortese, Dodd, Durazo, Eggman, Glazer, Gonzalez, Hurtado, Laird, Limón, McGuire, Menjivar, Min, Newman, Nguyen, Padilla, Portantino, Roth, Rubio, Skinner, Smallwood-Cuevas, Stern, Umberg, Wahab, Wiener, Wilk
ABS, ABST OR NV: Caballero, Dahle, Grove, Jones, Niello, Ochoa Bogh, Seyarto
ASSEMBLY FLOOR: 69-0-11
YES: Addis, Aguiar-Curry, Alvarez, Arambula, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Juan Carrillo, Wendy Carrillo, Cervantes, Connolly, Megan Dahle, Mike Fong, Friedman, Gabriel, Gallagher, Garcia, Gipson, Grayson, Haney, Hart, Holden, Hoover, Irwin, Jackson, Jones-Sawyer, Kalra, Lee, Low, Lowenthal, Maienschein, Mathis, McCarty, McKinnor, Muratsuchi, Stephanie Nguyen, Ortega, Pacheco, Papan, Pellerin, Petrie-Norris, Quirk-Silva, Ramos, Rendon, Reyes, Luz Rivas, Rodriguez, Blanca Rubio, Santiago, Schiavo, Soria, Ta, Ting, Valencia, Villapudua, Waldron, Wallis, Ward, Weber, Wicks, Wilson, Wood, Zbur, Robert Rivas
ABS, ABST OR NV: lanis, Chen, Davies, Dixon, Essayli, Flora, Vince Fong, Lackey, Jim Patterson, Joe Patterson, Sanchez
UPDATED
VERSION: September 18, 2023
CONSULTANT: Kristene Mapile / HEALTH / (916) 319-2097 FN: 0002505
CONCURRENCE IN SENATE AMENDMENTS
CSA1 Bill Id:AB 907
Author:(Lowenthal)
As Amended Ver:July 3, 2023
Majority vote
SUMMARY
Requires a health care service plan (health plan) contract or health insurance policy to provide coverage for the prophylaxis, diagnosis, and treatment of Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS) and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) that is prescribed or ordered by the treating physician and surgeon. Prohibits coverage for PANDAS and PANS from being subject to a copayment, coinsurance, deductible, or other cost sharing that is greater than that applied to other benefits. Prohibits a plan or insurer from denying or delaying coverage for PANDAS or PANS therapies because the enrollee or insured previously received treatment for PANDAS or PANS or was diagnosed with or received treatment for the condition under a different diagnostic name.
Senate Amendments
Clarify that the requirement for coverage of PANDAS and PANS is as prescribed or ordered by the treating physician and surgeon (rather than provider).
COMMENTS
According to the California Health Benefits Review Program (CHBRP), PANDAS/PANS are terms used to describe a subset of children with symptoms that include a sudden onset of a collection of neuropsychiatric symptoms co-occurring with obsessive-compulsive disorder (OCD) and/or tic disorders usually following an infection. PANDAS, currently classified as a subset of PANS, is hypothesized by some to be triggered by an autoimmune response to Group A Streptococcal (Strep) bacteria (which cause Strep throat or soft tissue infections).
Prevalence. PANDAS/PANS has been primarily described in children between the ages of three and 12 years; however, the exact prevalence and age distribution of PANDAS/PANS is unknown. Because OCD is a required symptom for the diagnosis of PANDAS and PANS, it is thought their prevalence can be estimated as a subset of the prevalence of pediatric OCD. Epidemiological research estimates that 0.5% to 5% of children in the United States are affected by OCD. PANDAS/PANS is uncommon and despite the first publication on the topic occurring in 1998, it remains unfamiliar to much of the clinical community. Clinicians commonly involved in diagnosing PANDAS/PANS may include a family physician, pediatrician, pediatric nurse practitioner, pediatric neurologist, pediatric psychiatrist, neurodevelopmental pediatrician, pediatric rheumatologist, and pediatric allergist/immunologist. Despite the wide variety of clinicians listed, many are unfamiliar with the syndromes and how to diagnose or treat them. There are 10 PANDAS/PANS clinics nationwide with two located in California (Stanford and University of California, Los Angeles (UCLA)). Due to the lack of diagnostic laboratory or imaging tests specific to PANDAS/PANS, and the overlap of symptoms with multiple conditions, the diagnostic process for these syndromes is challenging.
Barriers. Barriers for the diagnosis and treatment of PANDAS/PANS include the lack of evidence on effective treatment options. The lack of clinicians familiar with PANDAS and PANS contributes to long distance travel (and associated travel expenses) for families seeking care. PANDAS/PANS symptoms overlap with symptoms of other conditions, thus the lack of a definitive test and reliance on a differential diagnosis can lead to delayed diagnosis. Misdiagnosis, and children's suppression of behaviors during assessments are also treatment barriers in PANDAS/PANS. Treatment for moderate-to-severe PANDAS/PANS generally requires pediatric specialists, and ideally, coordinated care among treating clinicians who may be in different care settings. For patients with mild or moderate cases, weekly therapy with Cognitive Behavioral Therapy (CBT), or outpatient daily therapy may be prescribed, but due to pediatric behavioral health workforce shortages in California, both may be difficult to access. For patients with more severe cases, space in inpatient day programs or hospitalizations, where treatment may last from one week to months, may be difficult to obtain due to California's shortage of pediatric psychiatric care clinicians and inpatient and treatment beds.
CHBRP notes that this bill requires coverage of PANDAS and PANS to adhere to treatment recommendations in clinical practice guidelines and evidence-based standards; the guidelines developed by the aforementioned groups are consensus guidelines. Evidence-based guidelines make statements that are informed by a systematic review of the evidence and an assessment of the benefits and harms of alternative options. Consensus guidelines are developed by an independent panel of experts with experience in the condition(s), usually multidisciplinary, convened to review the research literature in an evidence-based manner for the purpose of advancing the understanding of an issue, procedure or method. The key difference between the development of the two types of guidelines appears to be that when the evidence is of high quality, some guideline panels rely on the evidence review to guide their recommendations and the process is evidence-based. However, when the evidence is very limited and hence of low quality or very low quality, some guideline panels rely primarily on clinical experience and the process is consensus-based.
CHBRP found clinical practice guidelines from three different organizations; all recognize the syndromes' range of severity (mild, moderate, severe) and recommend similar, but not perfectly aligned, treatments.
- CHBRP analysis. CHBRP reviewed this bill and states the following in its analysis:
- Impact on expenditures. This bill increases total net annual expenditures by total net annual $2,990,000 or total net annual 0.0020% for enrollees with Department of Managed Health Care (DMHC)-regulated plans (including DMHC-regulated Medi-Cal) and California Department of Insurance (CDI)-regulated policies. Premiums for enrollees in individual plans purchased through Covered California would increase by a total of $69,000 in annual expenditures.
- Medi-Cal. For this analysis, CHBRP has included potential impacts on Medi-Cal beneficiaries. In addition to the expected increase of $1.47 million in premiums, CHBRP is estimating for the 8.8 million Medi-Cal beneficiaries enrolled in DMHC-regulated plans (a figure that represents a 0.005% increase in premiums), it seems reasonable to assume that a population proportional increase of $370,000 would occur for the 2.0 million beneficiaries enrolled in county organized health systems (COHS) managed care.
- CalPERS. For enrollees associated with CalPERS in DMHC-regulated plans, premiums would increase by 0.001% ($0.01 per member per month, or $83,000 total increase in expenditures).
- Medical effectiveness. CHBRP analyzed the strength of evidence for the effectiveness of antibiotics, psychotropic medications, cognitive behavioral therapy, plasma exchange, IVIg and other immunomodulating medications addressed by this bill, specifically, for children affected by PANDAS/PANS. Overall, the evidence is insufficient or inconclusive that any of these treatments are effective at reducing prominent symptoms, such as OCD symptoms, tics, or eating restrictions, for pediatric patients with PANDAS/PANS. The body of research on PANDAS and PANS is small (number of studies and sample sizes of available studies) compared with many other diseases and conditions. Additional studies involving controlled clinical trials, larger sample sizes, and clear eligibility criteria are necessary to determine which treatments are effective for children with PANDAS/PANS. More specifically, CHBRP found insufficient evidence on the effectiveness of CBT, psychotropics, Non-steroidal anti-inflammatory drugs, corticosteroids, plasma exchange, rituximab, mycophenolate mofetil, and vitamin D in reducing or eliminating the prominent symptoms associated with PANDAS/PANS. CHBRP found inconclusive evidence on the effectiveness of antibiotics and IVIg in reducing or eliminating the prominent symptoms associated with PANDAS/PANS. Each of the medications reviewed for this analysis is associated with a variety of side effects and harms.
- Impact on expenditures. This bill increases total net annual expenditures by total net annual $2,990,000 or total net annual 0.0020% for enrollees with Department of Managed Health Care (DMHC)-regulated plans (including DMHC-regulated Medi-Cal) and California Department of Insurance (CDI)-regulated policies. Premiums for enrollees in individual plans purchased through Covered California would increase by a total of $69,000 in annual expenditures.
According to the Author
Despite published PANDAS/PANS treatment guidelines that established the standard of care in 2017, insurers have continued to adhere to their own policy statements forbidding authorization of immune-focused treatments like IVIg. As a result, treatments are denied routinely without real consideration. When a prescriber or family appeals, insurers typically uphold their denial, claiming "lack of medical necessity," or "treatment is experimental." Reviewers working for insurers are often nurses or pharmacists, not physicians, and even when an insurer engages the service of a physician to determine authorization, the physician reviewer generally lacks experience in this complex, uncommon, and devastating disorder. A typical delay in receiving IVIg due to insurance denials is measured in months, if not years. Many families give up. Meanwhile, most PANS/PANDAS sufferers cannot attend school or require intensive academic accommodations such as home hospital school. They may be hospitalized medically or psychiatrically, resulting in more cost and unnecessary suffering. They may accumulate permanent neurological damage. Their parents are often unable to work and may require state unemployment or family medical leave benefits. The author states children lucky enough to have parents with financial resources to pay out of pocket, or the savvy and persistence necessary to battle the protracted appeals process, recover well with appropriate treatment. Families who lack these resources endure financial ruin, possible child abuse allegations, police "wellness checks" that go awry, and even successful suicides. According to the author, this last sad fact has led to the establishment of the POND Brain Bank at Georgetown University, where the brains of three deceased young PANDAS/PANS patients are now contributing to scientific knowledge. Ten states have passed legislation similar to this bill since 2017, including two thus far in 2023. Without legislation, insurers have shown no willingness to grant timely and medically indicated treatment to PANS/PANDAS children. As a result, the author concludes that families continue to suffer unnecessarily and the state continues to incur costs related to special education and parental loss of employment and productivity.
Arguments in Support
PANDAS Physicians Network (PPN) is non-profit organization that maintains the industry standard PPN Guidelines for Diagnostics and Therapeutics, fosters continuous education and communication within the multi-disciplinary medical community and sponsors research for developing diagnostic tests, treatment protocols, and ultimately a cure for PANS and PANDAS. With PANS/PANDAS, an infection triggers a misdirected immune response causing inflammation in the brain. Psychiatric and neurologic symptoms manifest due to the inflammation. The hallmark trait of PANS/PANDAS is the abrupt and severe onset of OCD and/or severe eating restrictions. These primary symptoms are accompanied by other emotional and behavioral changes, frequent urination, tics, motor abnormalities and/or handwriting changes. PANS and PANDAS are treatable. Early intervention and treatment are keys to easing suffering, significantly improving mental health, shortening the duration of the illness, and laying the foundation for a long-term full recovery. Lack of treatment may lead to ongoing, worsening psychological distress, school and family disruption, psychiatric hospitalization, dramatic weight loss resulting in the need for a feeding tube or intravenous hydration, and/or an evolution of the illness into a chronic state. In severe cases, PANS/PANDAS children have lost their lives to suicide. This is preventable.
Arguments in Opposition
The California Association of Health Plans, the Association of California Life and Health Insurance Companies, and America's Health Insurance Plans write that state mandates increase costs of coverage, especially for families who buy coverage without subsidies, small business owners who cannot or do not wish to self-insure, and California taxpayers who foot the bill for the state's share of those mandates. Health plans compete for business based on innovative benefit designs that increase access to care, improve quality, and contain costs. The opposition states mandate will increase costs and limit flexibility for employers. Faced with higher costs, employers must make difficult decisions about whether to absorb premium increases or seek alternative coverage options. The Department of Finance is opposed to this bill, as it creates new costs and pressures to the Managed Care Fund not included in the 2023-24 budget plan. DMHC notes concerns that as drafted, this bill may be difficult to interpret and enforce. Additionally, the Department believes this type of disease-specific statute could create disparities and inequities for individuals that experience other health conditions, while increasing health care costs for all enrollees. The CHBRP analysis notes concerns with the medical effectiveness of treatments addressed by this bill. The analysis noted either insufficient or inconclusive evidence that any of the treatments included in this bill are effective at reducing prominent symptoms for pediatric patients with PANDAS/PANS.
FISCAL COMMENTS
According to the Senate Appropriations Committee,
- DMHC estimates costs to be approximately $157,000 in fiscal year (FY) 2023-24, $990,000 in FY 2024-25, and $1,014,000 in FY 2025-26 and annually thereafter for state operations (Managed Care Fund).
- CDI estimates costs of $7,000 in FY 2023-24 for state operations (Insurance Fund).
- Unknown, ongoing costs, likely low millions, for the Medi-Cal program to provide the services (General Fund and federal funds).
VOTES:
ASM HEALTH: 11-0-4
YES: Wood, Waldron, Aguiar-Curry, Boerner, Wendy Carrillo, Maienschein, McCarty, Rodriguez, Santiago, Villapudua, Weber
ABS, ABST OR NV: Arambula, Flora, Vince Fong, Joe Patterson
ASM APPROPRIATIONS: 12-1-3
YES: Holden, Bryan, Calderon, Wendy Carrillo, Mike Fong, Hart, Lowenthal, Mathis, Papan, Pellerin, Weber, Ortega
NO: Dixon
ABS, ABST OR NV: Megan Dahle, Robert Rivas, Sanchez
ASSEMBLY FLOOR: 69-0-11
YES: Addis, Aguiar-Curry, Alvarez, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Juan Carrillo, Wendy Carrillo, Cervantes, Connolly, Megan Dahle, Essayli, Mike Fong, Friedman, Gabriel, Gallagher, Garcia, Gipson, Grayson, Haney, Hart, Holden, Hoover, Irwin, Jackson, Jones-Sawyer, Kalra, Lee, Low, Lowenthal, Maienschein, Mathis, McCarty, McKinnor, Muratsuchi, Stephanie Nguyen, Ortega, Pacheco, Papan, Pellerin, Petrie‑Norris, Quirk-Silva, Ramos, Reyes, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Santiago, Schiavo, Soria, Ta, Ting, Valencia, Villapudua, Waldron, Wallis, Ward, Weber, Wicks, Wilson, Wood, Zbur, Rendon
ABS, ABST OR NV: Alanis, Arambula, Chen, Davies, Dixon, Flora, Vince Fong, Lackey, Jim Patterson, Joe Patterson, Sanchez
UPDATED
VERSION: July 3, 2023
CONSULTANT: Kristene Mapile / HEALTH / (916) 319-2097 FN: 0001705
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | AB 907 |
THIRD READING
Bill No: AB 907
Author: Lowenthal (D)
Amended: 7/3/23 in Senate
Vote: 21
SENATE HEALTH COMMITTEE: 11-0, 6/28/23
AYES: Eggman, Nguyen, Glazer, Gonzalez, Hurtado, Limón, Menjivar, Roth, Rubio, Wahab, Wiener
NO VOTE RECORDED: Grove
SENATE APPROPRIATIONS COMMITTEE: 5-0, 9/1/23
AYES: Portantino, Ashby, Bradford, Wahab, Wiener
NO VOTE RECORDED: Jones, Seyarto
ASSEMBLY FLOOR: 69-0, 5/31/23 - See last page for vote
SUBJECT: Coverage for PANDAS and PANS
SOURCE: California Coalition for PANS/PANDAS Advocacy
DIGEST:
This bill requires a health plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2024 to provide coverage for the prophylaxis, diagnosis, and treatment of Pediatric Autoimmune Neuropsychiatric Disorder Associated (PANDAS) with Streptococcal Infections and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) that is prescribed or ordered by a treating physician. Prohibits coverage for PANDAS and PANS from being subject to a copayment, coinsurance, deductible, or other cost sharing that is greater than that applied to other benefits provided by the contract.
ANALYSIS: Existing law establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 (Knox-Keene Act) and the California Department of Insurance (CDI) to regulate health and other insurers. [HSC §1340, et seq., and INS §106, et seq.]
This bill:
- Requires a health plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2024, to provide coverage for the prophylaxis, diagnosis, and treatment of PANDAS/PANS that is prescribed or ordered by a treating physician. Requires treatment for PANDAS/PANS to include antibiotics, medication, and behavioral therapies to manage neuropsychiatric symptoms, immunomodulating medicines, plasma exchange, and intravenous immunoglobulin (IVIG) therapy.
- Prohibits coverage for PANDAS/PANS from being subject to a copayment, coinsurance, deductible, or other cost sharing that is greater than that applied to other benefits provided by the contract.
- Prohibits a health plan or insurer from denying or delaying coverage for PANDAS/PANS therapies because the enrollee or insured previously received treatment, including the same or similar treatment, or because the enrollee or insured was diagnosed with or received treatment for their condition under a different diagnostic name, including autoimmune encephalopathy.
- Requires coverage for PANDAS/PANS to adhere to the treatment recommendations developed by a consortium of medical professionals convened to research, identify, and publish clinical practice guidelines and evidence-based standards for the diagnosis and treatment of those disorders.
- Prohibits a health plan or insurer from limiting coverage of immunomodulating therapies for PANDAS/PANS in a manner that is inconsistent with the treatment recommendations described in 4) above, and from requiring a trial of therapies that treat only neuropsychiatric symptoms before authorizing coverage of immunomodulating therapies pursuant to this bill.
- Requires, for billing and diagnostic purposes, PANDAS/PANS to be coded in a specified manner, and if PANDAS/PANS is known by a different common name in the future, permits it to be coded under that name and requires this bill to apply to that disorder or syndrome.
Comments
Author’s statement. According to the author, despite published PANDAS/PANS treatment guidelines that established the standard of care in 2017, insurers have continued to adhere to their own policy statements forbidding authorization of immune-focused treatments like IVIG. As a result, treatments are denied routinely without real consideration. Reviewers working for insurers generally lack experience in this complex, uncommon, and devastating disorder. A typical delay in receiving IVIG due to insurance denials is measured in months, if not years. Many families give up. Meanwhile, most PANS/PANDAS sufferers cannot attend school or require intensive academic accommodations such as home hospital school. They may be hospitalized medically or psychiatrically, resulting in more cost and unnecessary suffering. They may accumulate permanent neurological damage. Their parents are often unable to work and may require state unemployment or family medical leave benefits. Ten states have passed legislation similar to this bill since 2017, including two thus far in 2023. Without legislation, insurers have shown no willingness to grant timely and medically indicated treatment to PANS/PANDAS children. As a result, families continue to suffer unnecessarily and the state continues to incur costs related to special education and parental loss of employment and productivity.
Independent Medical Review. California Health Benefits Review Program (CHBRP) reviewed the state’s Independent Medical Review (IMR) determinations since 2014 and found 29 related to coverage of treatment for PANDAS/PANs, and autoimmune encephalitis. All determinations were specific to coverage of IVIG. A total of 15 IMRs overturned the decision of the health plan for enrollees requesting coverage for IVIG, based on the refractory nature of the patient’s condition and sufficient evidence showing lack of improvement following first-line therapies. The health plans’ decisions were upheld in 14 instances where enrollees requested coverage of IVIG either due to insufficient medical evidence and/or lack of clinical evidence supporting the patient’s diagnosis and therefore medical necessity for the treatment. CHBRP found five determinations specific to the diagnosis of PANDAS/PANS. None of the medical reviews were for coverage requests of diagnostic tests or services recommended by any of the guidelines used by CHBRP for this analysis.
CHBRP analysis. AB 1996 (Thomson, Chapter 795, Statutes of 2002) requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996, and reviewed this bill. Key findings include:
- Medical effectiveness: Overall, the evidence is insufficient or inconclusive that any of these treatments are effective at reducing prominent symptoms, such as obsessive compulsive disorder symptoms, tics, or eating restrictions, for pediatric patients with PANDAS/PANS. The body of research on PANDAS/PANS is small (number of studies and sample sizes of available studies) compared with many other diseases and conditions. Additional studies involving controlled clinical trials, larger sample sizes, and clear eligibility criteria are necessary to determine which treatments are effective for children with PANDAS/PANS. More specifically, CHBRP found insufficient evidence on the effectiveness of cognitive behavioral therapy (CBT), psychotropics, NSAIDs, corticosteroids, plasma exchange, rituximab, mycophenolate mofetil, and vitamin D in reducing or eliminating the prominent symptoms associated with PANDAS/PANS. CHBRP found inconclusive evidence on the effectiveness of antibiotics and IVIG in reducing or eliminating the prominent symptoms associated with PANDAS/PANS. Each of the medications reviewed for this analysis is associated with a variety of side effects and harms.
- Utilization: CHBRP estimates that at baseline, 15,410 enrollees use diagnostic tests for PANDAS/PANS. These include various blood tests, throat cultures, and nose swabs. CHBRP estimates that for every 23 children tested for PANDAS/PANS using these diagnostic tests, one child is diagnosed with PANDAS/PANS and 22 children are not given this diagnosis. Given that 100% of enrollees already have baseline coverage, CHBRP estimates no changes in utilization for these diagnostic tests. At baseline, CHBRP estimates that 670 enrollees have a PANDAS/PANS diagnosis. Among these enrollees, average annual utilization of oral prescription medications used for the treatment and management of neuropsychiatric symptoms (including medications such as antibiotics, steroids, NSAIDs, and psychotropics) is 17.8 prescriptions, each with a 30-day supply. At baseline, annual utilization of CBT is 20 visits per year. Given that 100% of enrollees already have baseline coverage for these medications and behavioral health therapies such as CBT, CHBRP estimated no changes in utilization of these specific medications and CBT services postmandate. CHBRP estimates that IVIG, rituximab, and plasma exchange have extremely limited use at baseline. CHBRP estimates that average annual utilization of IVIG among all enrollees with PANDAS/PANS would increase to 0.7 infusion therapy sessions per year. This results in an estimated 90 enrollees with moderate or severe PANDAS/PANS utilizing IVIG at least once per year, with greater expected utilization among those with severe PANDAS/PANS. CHBRP estimates that average annual utilization of rituximab would increase to 0.1 infusion therapy sessions. This results in an estimated 22 enrollees with severe PANDAS/PANS utilizing an estimated average of 3 rituximab infusions per year. CHBRP estimated no change in the use of plasma exchange services given their low availability and the lack of evidence of their effectiveness in PANDAS/PANS.
- Medi-Cal: For this analysis, CHBRP has included potential impacts on Medi-Cal beneficiaries. In addition to the expected increase of $1.47 million in premiums CHBRP is estimating for the 8.8 million Medi-Cal beneficiaries enrolled in DMHC-regulated plans (a figure that represents a 0.005% increase in premiums), it seems reasonable to assume that a population proportional increase of $370,000 would occur for the two million beneficiaries enrolled in county organized health systems managed care.
- Impact on expenditures: This bill increases total net annual expenditures by $2,990,000. Premium expenditures would increase for employers, employees, individuals and families by $1,366,000. Cost sharing for covered benefits would be $153,000.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: Yes
According to the Senate Appropriations Committee:
- DMHC estimates costs to be approximately $157,000 in fiscal year (FY) 2023-24, $990,000 in FY 2024-25, and $1,014,000 in FY 2025-26 and annually thereafter for state operations (Managed Care Fund).
- CDI estimates costs of $7,000 in FY 2023-24 for state operations (Insurance Fund).
- Unknown, ongoing costs, likely low millions, for the Medi-Cal program to provide the services (General Fund and federal funds).
SUPPORT: (Verified 9/1/23)
California Coalition for PANS/PANDAS Advocacy (source)
Alliance to Solve Pans & Immune-related Encephalopathies
Autoimmune Registry
California Children’s Hospital Association
California Federation of Teachers, AFL-CIO
California Health Coalition Advocacy
California Life Sciences
California School Nurses Organization
California Teamsters Public Affairs Council
International Longshore and Warehouse Union
Memorial Care Health System
Moleculera Labs
Northwest PANDAS/PANS Network
PANDAS Physicians Network
SAG-AFTRA
Stand Up Sacramento County
The Alex Manfull Fund
The European Immuno-neuropsychiatric Association
The PACE Foundation
Virginia Alliance for Pans Pandas Action
Several individuals
OPPOSITION: (Verified 9/1/23)
America's Health Insurance Plans
Association of California Life & Health Insurance Companies
California Association of Health Plans
Department of Finance
ARGUMENTS IN SUPPORT: The PANDAS Physicians Network writes that, with PANS/PANDAS, an infection triggers a misdirected immune response causing inflammation in the brain. Psychiatric and neurologic symptoms manifest due to the inflammation. The hallmark trait of PANS/PANDAS is the abrupt and severe onset of obsessive compulsive disorder and/or severe eating restrictions. These primary symptoms are accompanied by other emotional and behavioral changes, frequent urination, tics, motor abnormalities and/or handwriting changes. PANS/PANDAS are treatable. Early intervention and treatment are keys to easing suffering, significantly improving mental health, shortening the duration of the illness, and laying the foundation for a long-term full recovery. Lack of treatment may lead to ongoing, worsening psychological distress, school and family disruption, psychiatric hospitalization, dramatic weight loss resulting in the need for a feeding tube or intravenous hydration, and/or an evolution of the illness into a chronic state. In severe cases, PANS/PANDAS children have lost their lives to suicide. This is preventable.
Stand up Sacramento County writes there is a rising number of cases of PANS/PANDAS and too many are being written off as obsessive compulsive disorder or simply being neurodivergent. This bill puts measures in place for a system of coding and would help minimize the financial burden for families that is super high given the kids need antibiotics, steroids or even IVIG, to help reset the immune system. The whole process is a nightmare for parents, especially those of poor economic means, to get to the root of the problem and to heal their child.
The Alex Manfull Fund writes despite the solid research, clinical experiences and successful treatment outcomes, insurance companies continue to attempt to substitute their judgment for that of providers who have familiarized themselves with the research in the course of treating their patients.
ARGUMENTS IN OPPOSITION: The California Association of Health Plans, the Association of California Life & Health Insurance Companies, and America’s Health Insurance Plans write that they are concerned that this bill will require health plans/insurers to provide coverage for all treatments identified for these conditions regardless of whether or not they meet the basic medical necessity standard, while simultaneously prohibiting health plans/insurers from imposing any limitations on access with respect to the volume of treatments. This is especially concerning as PANDAS and PANS are both extremely challenging to definitively diagnose. Currently, there is no existing diagnostic test to specifically confirm a diagnosis for either PANDAS or PANS. Generally, clinicians use differential diagnostic processes to not only confirm a diagnosis, but also rule out other conditions with similar symptoms, such as obsessive compulsive disorder, among other diagnoses. ICD-10 codes do exist for PANDAS under the definition of “disorders involving immune mechanisms”, while PANS has no specific diagnostic. Additionally, national billing codes do not currently exist to reimburse for these specific services. In fact, in the absence of a nationally recognized billing code for these conditions, this bill would require health plans/insures to utilize a billing code for a different, albeit similar condition (autoimmune encephalitis), to reimburse for any services. Lastly, this bill is one of numerous health plan/insurance mandates to be introduced this year. Admittedly, while this bill is not the most expensive mandate introduced this year, it is important to consider the cumulative impacts these bills have on the overall cost of healthcare. Just this year alone the estimated increase to premiums is at least $742,533,000 with projected additional increases in out years. Ultimately, these bills will harm affordability and access for small businesses and individual market consumers. The Department of Finance is opposed to this bill, as it creates new costs and pressures to the Managed Care Fund not included in the 2023-24 budget plan. Additionally, Finance has policy concerns. DMHC notes concerns that as drafted, this bill may be difficult to interpret and enforce. Additionally, DMHC believes this type of disease-specific statute could create disparities and inequities for individuals that experience other health conditions, while increasing health care costs for all enrollees. The April 20, 2023 CHBRP analysis notes concerns with the medical effectiveness of treatments addressed by this bill. The analysis noted either insufficient or inconclusive evidence that any of the treatments included in this bill are effective at reducing prominent symptoms for pediatric patients with PANDAS/PANS. |
ASSEMBLY FLOOR: 69-0, 5/31/23
AYES: Addis, Aguiar-Curry, Alvarez, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Juan Carrillo, Wendy Carrillo, Cervantes, Connolly, Megan Dahle, Essayli, Mike Fong, Friedman, Gabriel, Gallagher, Garcia, Gipson, Grayson, Haney, Hart, Holden, Hoover, Irwin, Jackson, Jones-Sawyer, Kalra, Lee, Low, Lowenthal, Maienschein, Mathis, McCarty, McKinnor, Muratsuchi, Stephanie Nguyen, Ortega, Pacheco, Papan, Pellerin, Petrie-Norris, Quirk-Silva, Ramos, Reyes, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Santiago, Schiavo, Soria, Ta, Ting, Valencia, Villapudua, Waldron, Wallis, Ward, Weber, Wicks, Wilson, Wood, Zbur, Rendon
NO VOTE RECORDED: Alanis, Arambula, Chen, Davies, Dixon, Flora, Vince Fong, Lackey, Jim Patterson, Joe Patterson, Sanchez
Prepared by: Teri Boughton / HEALTH / (916) 651-4111
9/4/23 9:40:15
**** END ****
SENATE COMMITTEE ON APPROPRIATIONS
Senator Anthony Portantino, Chair
2023 - 2024 Regular Session
AB 907 (Lowenthal) - Coverage for PANDAS and PANS
Version: July 3, 2023 | Policy Vote: HEALTH 11 - 0 |
Urgency: No | Mandate: Yes |
Hearing Date: July 10, 2023 | Consultant: Agnes Lee |
Bill Summary:
AB 907 would require a health plan or insurer to provide coverage for the prophylaxis, diagnosis, and treatment of Pediatric Autoimmune Neuropsychiatric Disorder Associated (PANDAS) with Streptococcal Infections and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS).
Fiscal Impact:
- The Department of Managed Health Care (DMHC) estimates costs to be approximately $157,000 in 2023-24, $990,000 in 2024-25, and $1,014,000 in 2025-26 and annually thereafter for state operations (Managed Care Fund).
- The California Department of Insurance (CDI) estimates costs of $7,000 in 2023-24 for state operations (Insurance Fund).
- Unknown, ongoing costs, likely low millions, for the Medi-Cal program to provide the services (General Fund and federal funds).
Background:
PANDAS/PANS are terms used to describe a subset of children with symptoms that include a sudden onset of obsessive-compulsive disorder (OCD) and/or tic disorders co-occurring with a collection of neuropsychiatric symptoms usually following an infection. Children may also become moody or irritable, or experience anxiety attacks, separation anxiety, rage, fatigue, phobias, insomnia, joint or muscle pain, or eating disorders.
PANDAS, currently classified as a subset of PANS, is hypothesized by some to be triggered by an autoimmune response to Group A Streptococcal bacteria (which cause strep throat or soft tissue infections). PANS is hypothesized to be triggered by causes other than Group A Streptococcus infection. Much remains unknown about PANDAS and PANS, and controversy remains regarding whether PANDAS differs enough from OCD/tic disorder and other neuropsychiatric disorders to warrant a different diagnostic category.
PANDAS/PANS has been primarily described in children between the ages of 3 and 12 years; however, the exact prevalence and age distribution of PANDAS/PANS is unknown. People over the age of 17 may also present with symptoms similar to those of PANDAS/PANS or have an initial diagnosis of either syndrome at a pediatric age that continues into adulthood.
Proposed Law:
Specific provisions of the bill would:
- Require, as specified, a health plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2024, to provide coverage for the prophylaxis, diagnosis, and treatment of PANDAS/PANS that is prescribed or ordered by a treating physician.
- Require treatment for PANDAS/PANS to include antibiotics, medication, and behavioral therapies to manage neuropsychiatric symptoms, immunomodulating medicines, plasma exchange, and intravenous immunoglobulin (IVIG) therapy.
- Prohibit coverage for PANDAS/PANS from being subject to a copayment, coinsurance, deductible, or other cost sharing that is greater than that applied to other benefits provided by the contract.
Staff Comments: The California Health Benefits Review Program (CHBRP) analysis of AB 907 (amended March 16, 2023) estimates an increase in total net annual expenditures of $2,990,000 for enrollees with DMHC-regulated plans and CDI-regulated policies. This includes an increase of $83,000 for CalPERS health plan premium costs. The CHBRP also estimates costs of $1,841,000 for the Medi-Cal program (includes DMHC-regulated and non-DMHC-regulated plans).
-- END --
SENATE COMMITTEE ON HEALTH
Senator Dr. Susan Talamantes Eggman, Chair
BILL NO: AB 907
AUTHOR: | Lowenthal | ||
VERSION: | June 15, 2023 | ||
HEARING DATE: | June 28, 2023 | ||
CONSULTANT: | Teri Boughton | ||
SUBJECT: Coverage for PANDAS and PANS
SUMMARY:
Requires a health plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2024 to provide coverage for the prophylaxis, diagnosis, and treatment of Pediatric Autoimmune Neuropsychiatric Disorder Associated (PANDAS) with Streptococcal Infections and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) that is prescribed or ordered by a treating physician. Prohibits coverage for PANDAS and PANS from being subject to a copayment, coinsurance, deductible, or other cost sharing that is greater than that applied to other benefits provided by the contract.
Existing law:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 (Knox-Keene Act) and the California Department of Insurance (CDI) to regulate health and other insurers. [HSC §1340, et seq., and INS §106, et seq.]
- Establishes, as California's essential health benefits benchmark, the Kaiser Small Group Health Maintenance Organization, existing California mandates, and ten federal Patient Protection and Affordable Care Act mandated benefits. [HSC §1367.005 and INS §10112.27]
- Requires the criteria or guidelines used by health plans and insurers, or any entities with which plans or insurers contract for utilization review (UR) or utilization management (UM) functions, to determine whether to authorize, modify, or deny health care services to:
- Be developed with involvement from actively practicing health care providers;
- Be consistent with sound clinical principles and processes;
- Be evaluated, and updated if necessary, at least annually;
- If used as the basis of a decision to modify, delay, or deny services in a specified case under review, be disclosed to the provider and the enrollee or insured in that specified case; and,
- Be available to the public upon request. [HSC §1363.5 and INS §10123.135]
- Requires reviews, for purposes of Independent Medical Review (IMR), to determine whether the disputed health care service was medically necessary based on the specific medical needs of the enrollee or insured and any of the following:
- Peer-reviewed scientific and medical evidence regarding the effectiveness of the disputed service;
- Nationally recognized professional standards;
- Expert opinion;
- Generally accepted standards of medical practice; or,
- Treatments that are likely to provide a benefit to a patient for conditions for which other treatments are not clinically efficacious. [HSC §1374.33 and INS §10169.3]
- Requires a health plan or insurer that provides or arranges for the provision of hospital or physician services, including a specialized mental health plan, and a policy of health insurance to comply with specified timely access requirements. [HSC §1367.03 and INS §10133.54]
This bill:
- Requires a health plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2024, to provide coverage for the prophylaxis, diagnosis, and treatment of PANDAS/PANS that is prescribed or ordered by a treating physician. Requires treatment for PANDAS/PANS to include antibiotics, medication, and behavioral therapies to manage neuropsychiatric symptoms, immunomodulating medicines, plasma exchange, and intravenous immunoglobulin (IVIG) therapy.
- Prohibits coverage for PANDAS/PANS from being subject to a copayment, coinsurance, deductible, or other cost sharing that is greater than that applied to other benefits provided by the contract.
- Requires any required authorization for PANDAS/PANS prophylaxis, diagnosis, or treatment to be provided in a timely manner that is appropriate for the severity of an enrollee’s condition pursuant to timely access to care requirements, as specified.
- Prohibits a health plan or insurer from denying or delaying coverage for PANDAS/PANS therapies because the enrollee or insured previously received treatment, including the same or similar treatment, or because the enrollee or insured was diagnosed with or received treatment for their condition under a different diagnostic name, including autoimmune encephalopathy.
- Requires coverage for PANDAS/PANS to adhere to the treatment recommendations developed by a consortium of medical professionals convened to research, identify, and publish clinical practice guidelines and evidence-based standards for the diagnosis and treatment of those disorders.
- Prohibits a health plan or insurer from limiting coverage of immunomodulating therapies for PANDAS/PANS in a manner that is inconsistent with the treatment recommendations described in 5) above, and from requiring a trial of therapies that treat only neuropsychiatric symptoms before authorizing coverage of immunomodulating therapies pursuant to this bill.
- Requires, for billing and diagnostic purposes, PANDAS/PANS to be coded as autoimmune encephalitis until the American Medical Association and the federal Centers for Medicare and Medicaid Services create and assign a specific code or codes for PANDAS/PANS. After the creation of that code, permits PANDAS/PANS to be coded as autoimmune encephalitis, PANDAS, or PANS. If PANDAS/PANS is known by a different common name in the future, permits it to be coded under that name and requires this bill to apply to that disorder or syndrome.
- Exempts a specialized health plan contract or health insurance policy that does not cover an essential health benefit, as defined, or a Medicare supplement policy.
FISCAL EFFECT:
According to the Assembly Appropriations Committee:
CDI estimates costs of $7,000 for 0.1 position in fiscal year (FY) 2023-24 (Insurance Fund).
DMHC estimates it will need to add three full- time equivalents, and the total cost of this bill will be approximately:
- $157,000 in FY 2023-24;
- $990,000 in FY 2024-25; and,
- $1,014,000 in FY 2025-26 and annually thereafter (Managed Care Fund (MCF)).
DMHC notes generally, and depending on final enrollment data, a $1 million dollar increase to the MCF could result in a 2-cent increase per enrollee on assessments to full-service health plans and a 1-cent increase per enrollee to specialized health plans. To the extent this bill and others result in an additional assessment on health plans, consumers could face increased premiums as a result of this and other bills mandating coverage.
The California Health Benefits Review Program (CHBRP) estimates annual premiums for enrollees in individual plans purchased through Covered California would increase by a total of $69,000, a portion of which is paid by the state (General Fund, federal funds).
CHBRP estimates an increase of $1.47 million in premiums for enrollees in Medi-Cal managed care and $370,000 for those in Medi-Cal COHS managed care (General Fund and federal funds).
For enrollees associated with CalPERS in DMHC-regulated plans, CHBRP estimates premiums would increase by $83,000 (these costs are borne by enrollees and state and other government entities).
PRIOR VOTES:
Assembly Floor: | 69 - 0 |
Assembly Appropriations Committee: | 12 - 1 |
Assembly Health Committee: | 11 - 0 |
COMMENTS:
- Author’s statement. According to the author, despite published PANDAS/PANS treatment guidelines that established the standard of care in 2017, insurers have continued to adhere to their own policy statements forbidding authorization of immune-focused treatments like IVIG. As a result, treatments are denied routinely without real consideration. Reviewers working for insurers generally lack experience in this complex, uncommon, and devastating disorder. A typical delay in receiving IVIG due to insurance denials is measured in months, if not years. Many families give up. Meanwhile, most PANS/PANDAS sufferers cannot attend school or require intensive academic accommodations such as home hospital school. They may be hospitalized medically or psychiatrically, resulting in more cost and unnecessary suffering. They may accumulate permanent neurological damage. Their parents are often unable to work and may require state unemployment or family medical leave benefits. Ten states have passed legislation similar to this bill since 2017, including two thus far in 2023. Without legislation, insurers have shown no willingness to grant timely and medically indicated treatment to PANS/PANDAS children. As a result, families continue to suffer unnecessarily and the state continues to incur costs related to special education and parental loss of employment and productivity.
- IMR Process. An enrollee or insured can apply for IMR when they have filed a grievance with the plan, provider, or insurer and the decision was upheld or remains unresolved after 30 days. A grievance requiring expedited review can go to IMR after three days of the grievance process. Enrollees and insureds can apply for IMR when a) the provider has recommended a health care service as medically necessary; b) the enrollee or insured has received urgent care or emergency services that a provider determined was medically necessary; c) the enrollee has received experimental or investigational treatment for a serious condition; or, d) the enrollee or insured has been seen by an in-plan provider for the diagnosis or treatment of the medical condition and the disputed health care service has been denied, modified, or delayed by the plan or insurer or by one of its contracting providers, based on a decision that it is not medical necessary. IMR is free to the enrollee or insured, and in most cases decided within 30 days of IMR qualification and receipt of all required documentation. For more urgent situations, an expedited IMR can be requested and is usually decided within seven days after the supporting documentation is provided. An IMR can take longer if all of the medical records needed are not provided in a timely manner. In approximately 68% of IMR cases at the DMHC, the health plan’s denial of service was reversed by the health plan or overturned by the IMR organization and the enrollee received authorization for the requested service or treatment. If the IMR decision is in favor of the enrollee, the health plan must authorize the service or treatment within five business days. Both health plans and insurers must comply with the IMR requirements.
- IMR statistics. According to the DMHC Annual Report, in 2022, the DMHC Help Center assisted 128,405 health care consumers, and handled 12,266 complaints and 3,240 IMRs. Approximately 68% of consumers who submitted an IMR request to the DMHC Help Center received the service or treatment they requested. CDI’s Annual Report for 2021 indicates a total number of 191 IMR cases for 2021, in which 121 (63%) were overturned in favor of the insured.
CHBRP reviewed the state’s IMR determinations since 2014 and found 29 related to coverage of treatment for PANDAS/PANs, and autoimmune encephalitis. All determinations were specific to coverage of IVIG. A total of 15 IMRs overturned the decision of the health plan for enrollees requesting coverage for IVIG, based on the refractory nature of the patient’s condition and sufficient evidence showing lack of improvement following first-line therapies. The health plans’ decisions were upheld in 14 instances where enrollees requested coverage of IVIG either due to insufficient medical evidence and/or lack of clinical evidence supporting the patient’s diagnosis and therefore medical necessity for the treatment. CHBRP found five determinations specific to the diagnosis of PANDAS/PANS. None of the medical reviews were for coverage requests of diagnostic tests or services recommended by any of the guidelines used by CHBRP for this analysis. - CHBRP analysis. AB 1996 (Thomson, Chapter 795, Statutes of 2002) requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996, and reviewed this bill. Key findings include:
- Coverage impacts and enrollees covered. At baseline, 100% of enrollees with health insurance subject to this bill have coverage that includes diagnostic tests recommended by various guidelines related to PANDAS/PANS and would continue to have 100% coverage postmandate. At baseline, 100% of enrollees with health insurance subject to this bill would have coverage for antibiotics, oral prescription immunomodulatory medications, and behavioral therapies and medications for managing neuropsychiatric symptoms, consistent with recommendations for treatment of PANDAS/PANS under existing clinical guidelines, and 0% have coverage for intravenous immunomodulating therapies, including plasma exchange and IVIG therapy; postmandate 100% would have coverage for the aforementioned treatments.
- Medical effectiveness. Overall, the evidence is insufficient or inconclusive that any of these treatments are effective at reducing prominent symptoms, such as obsessive compulsive disorder symptoms, tics, or eating restrictions, for pediatric patients with PANDAS/PANS. The body of research on PANDAS/PANS is small (number of studies and sample sizes of available studies) compared with many other diseases and conditions. Additional studies involving controlled clinical trials, larger sample sizes, and clear eligibility criteria are necessary to determine which treatments are effective for children with PANDAS/PANS. More specifically, CHBRP found insufficient evidence on the effectiveness of cognitive behavioral therapy (CBT), psychotropics, NSAIDs, corticosteroids, plasma exchange, rituximab, mycophenolate mofetil, and vitamin D in reducing or eliminating the prominent symptoms associated with PANDAS/PANS. CHBRP found inconclusive evidence on the effectiveness of antibiotics and IVIG in reducing or eliminating the prominent symptoms associated with PANDAS/PANS. Each of the medications reviewed for this analysis is associated with a variety of side effects and harms.
- Utilization. CHBRP estimates that at baseline, 15,410 enrollees use diagnostic tests for PANDAS/PANS. These include various blood tests, throat cultures, and nose swabs. CHBRP estimates that for every 23 children tested for PANDAS/PANS using these diagnostic tests, one child is diagnosed with PANDAS/PANS and 22 children are not given this diagnosis. Given that 100% of enrollees already have baseline coverage, CHBRP estimates no changes in utilization for these diagnostic tests. At baseline, CHBRP estimates that 670 enrollees have a PANDAS/PANS diagnosis. Among these enrollees, average annual utilization of oral prescription medications used for the treatment and management of neuropsychiatric symptoms (including medications such as antibiotics, steroids, NSAIDs, and psychotropics) is 17.8 prescriptions, each with a 30-day supply. At baseline, annual utilization of CBT is 20 visits per year. Given that 100% of enrollees already have baseline coverage for these medications and behavioral health therapies such as CBT, CHBRP estimated no changes in utilization of these specific medications and CBT services postmandate. CHBRP estimates that IVIG, rituximab, and plasma exchange have extremely limited use at baseline. CHBRP estimates that average annual utilization of IVIG among all enrollees with PANDAS/PANS would increase to 0.7 infusion therapy sessions per year. This results in an estimated 90 enrollees with moderate or severe PANDAS/PANS utilizing IVIG at least once per year, with greater expected utilization among those with severe PANDAS/PANS. CHBRP estimates that average annual utilization of rituximab would increase to 0.1 infusion therapy sessions. This results in an estimated 22 enrollees with severe PANDAS/PANS utilizing an estimated average of 3 rituximab infusions per year. CHBRP estimated no change in the use of plasma exchange services given their low availability and the lack of evidence of their effectiveness in PANDAS/PANS.
- Medi-Cal. For this analysis, CHBRP has included potential impacts on Medi-Cal beneficiaries. In addition to the expected increase of $1.47 million in premiums CHBRP is estimating for the 8.8 million Medi-Cal beneficiaries enrolled in DMHC-regulated plans (a figure that represents a 0.005% increase in premiums), it seems reasonable to assume that a population proportional increase of $370,000 would occur for the two million beneficiaries enrolled in county organized health systems managed care.
- Impact on expenditures. This bill would increase total net annual expenditures by $2,990,000. Premium expenditures would increase for employers, employees, individuals and families by $1,366,000. Cost sharing for covered benefits would be $153,000.
- Essential health benefits. This bill would not require coverage for a new state benefit mandate that appears to exceed the definition of essential health benefits in California.
- Coverage impacts and enrollees covered. At baseline, 100% of enrollees with health insurance subject to this bill have coverage that includes diagnostic tests recommended by various guidelines related to PANDAS/PANS and would continue to have 100% coverage postmandate. At baseline, 100% of enrollees with health insurance subject to this bill would have coverage for antibiotics, oral prescription immunomodulatory medications, and behavioral therapies and medications for managing neuropsychiatric symptoms, consistent with recommendations for treatment of PANDAS/PANS under existing clinical guidelines, and 0% have coverage for intravenous immunomodulating therapies, including plasma exchange and IVIG therapy; postmandate 100% would have coverage for the aforementioned treatments.
- Support. The PANDAS Physicians Network writes with PANS/PANDAS, an infection triggers a misdirected immune response causing inflammation in the brain. Psychiatric and neurologic symptoms manifest due to the inflammation. The hallmark trait of PANS/PANDAS is the abrupt and severe onset of obsessive compulsive disorder and/or severe eating restrictions. These primary symptoms are accompanied by other emotional and behavioral changes, frequent urination, tics, motor abnormalities and/or handwriting changes. PANS/PANDAS are treatable. Early intervention and treatment are keys to easing suffering, significantly improving mental health, shortening the duration of the illness, and laying the foundation for a long-term full recovery. Lack of treatment may lead to ongoing, worsening psychological distress, school and family disruption, psychiatric hospitalization, dramatic weight loss resulting in the need for a feeding tube or intravenous hydration, and/or an evolution of the illness into a chronic state. In severe cases, PANS/PANDAS children have lost their lives to suicide. This is preventable. Stand up Sacramento County writes there is a rising number of cases of PANS/PANDAS and too many are being written off as obsessive compulsive disorder or simply being neurodivergent. This bill would put measures in place for a system of coding and would help minimize the financial burden for families that is super high given the kids need antibiotics, steroids or even IVIG, to help reset the immune system. The whole process is a nightmare for parents, especially those of poor economic means, to get to the root of the problem and to heal their child. The Alex Manfull Fund writes despite the solid research, clinical experiences and successful treatment outcomes, insurance companies continue to attempt to substitute their judgment for that of providers who have familiarized themselves with the research in the course of treating their patients.
- Opposition. The California Association of Health Plans, the Association of California Life and Health Insurance Companies, and America’s Health Insurance Plans write that they are concerned that this bill will require health plans/insurers to provide coverage for all treatments identified for these conditions regardless of whether or not they meet the basic medical necessity standard, while simultaneously prohibiting health plans/insurers from imposing any limitations on access with respect to the volume of treatments. This is especially concerning as PANDAS and PANS are both extremely challenging to definitively diagnose. Currently, there is no existing diagnostic test to specifically confirm a diagnosis for either PANDAS or PANS. Generally, clinicians use differential diagnostic processes to not only confirm a diagnosis, but also rule out other conditions with similar symptoms, such as obsessive compulsive disorder, among other diagnoses. ICD-10 codes do exist for PANDAS under the definition of “disorders involving immune mechanisms”, while PANS has no specific diagnostic. Additionally, national billing codes do not currently exist to reimburse for these specific services. In fact, in the absence of a nationally recognized billing code for these conditions, this bill would require health plans/insures to utilize a billing code for a different, albeit similar condition (autoimmune encephalitis), to reimburse for any services. Lastly, this bill is one of numerous health plan/insurance mandates to be introduced this year. Admittedly, while this bill is not the most expensive mandate introduced this year, it is important to consider the cumulative impacts these bills have on the overall cost of healthcare. Just this year alone the estimated increase to premiums is at least $742,533,000 with projected additional increases in out years. Ultimately, these bills will harm affordability and access for small businesses and individual market consumers.
- Amendments. An amendment is needed to clarify that this bill would not apply to specialized health plans or health insurance policies that cover dental and vision services, as drafted the current exemption in the bill is not clear.
SUPPORT AND OPPOSITION:
Support: California Coalition for PANS/PANDAS Advocacy (sponsor)
Alliance to Solve Pans & Immune-related Encephalopathies
Autoimmune Registry
California Children’s Hospital Association
California Federation of Teachers, AFL-CIO
California Health Coalition Advocacy
California Life Sciences
California School Nurses Organization
California Teamsters Public Affairs Council
International Longshore and Warehouse Union
Moleculera Labs
Memorial Care Health System
Northwest PANDAS/PANS Network
PANDAS Physician Network
Stand Up Sacramento County
The Alex Manfull Fund
The PACE Foundation
The European Immuno-neuropsychiatric Association
Virginia Alliance for Pans Pandas Action
Several individuals
Oppose: America's Health Insurance Plans
Association of California Life & Health Insurance Companies
California Association of Health Plans
-- END --
ASSEMBLY THIRD READING
ATR Bill Id:AB 907
Author:(Lowenthal)
As Amended Ver:March 16, 2023
Majority vote
SUMMARY
Requires a health care service plan (health plan) contract or health insurance policy to provide coverage for the prophylaxis, diagnosis, and treatment of Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS) and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) that is prescribed or ordered by a provider. Prohibits coverage for PANDAS and PANS from being subject to a copayment, coinsurance, deductible, or other cost sharing that is greater than that applied to other benefits. Prohibits a plan or insurer from denying or delaying coverage for PANDAS or PANS therapies because the enrollee or insured previously received treatment for PANDAS or PANS or was diagnosed with or received treatment for the condition under a different diagnostic name.
Major Provisions
COMMENTS
According to the California Health Benefits Review Program (CHBRP), PANDAS/PANS are terms used to describe a subset of children with symptoms that include a sudden onset of a collection of neuropsychiatric symptoms co-occurring with obsessive-compulsive disorder (OCD) and/or tic disorders usually following an infection. PANDAS, currently classified as a subset of PANS, is hypothesized by some to be triggered by an autoimmune response to Group A Streptococcal (Strep) bacteria (which cause Strep throat or soft tissue infections).
Prevalence. PANDAS/PANS has been primarily described in children between the ages of three and 12 years; however, the exact prevalence and age distribution of PANDAS/PANS is unknown. Because OCD is a required symptom for the diagnosis of PANDAS and PANS, it is thought their prevalence can be estimated as a subset of the prevalence of pediatric OCD. Epidemiological research estimates that 0.5% to 5% of children in the United States are affected by OCD. PANDAS/PANS is uncommon and despite the first publication on the topic occurring in 1998, it remains unfamiliar to much of the clinical community. Clinicians commonly involved in diagnosing PANDAS/PANS may include a family physician, pediatrician, pediatric nurse practitioner, pediatric neurologist, pediatric psychiatrist, neurodevelopmental pediatrician, pediatric rheumatologist, and pediatric allergist/immunologist. Despite the wide variety of clinicians listed, many are unfamiliar with the syndromes and how to diagnose or treat them. There are 10 PANDAS/PANS clinics nationwide with two located in California (Stanford and UCLA). Due to the lack of diagnostic laboratory or imaging tests specific to PANDAS/PANS, and the overlap of symptoms with multiple conditions, the diagnostic process for these syndromes is challenging.
Barriers. Barriers for the diagnosis and treatment of PANDAS/PANS include the lack of evidence on effective treatment options. The lack of clinicians familiar with PANDAS and PANS contributes to long distance travel (and associated travel expenses) for families seeking care. PANDAS/PANS symptoms overlap with symptoms of other conditions, thus the lack of a definitive test and reliance on a differential diagnosis can lead to delayed diagnosis. Misdiagnosis, and children's suppression of behaviors during assessments are also treatment barriers in PANDAS/PANS. Treatment for moderate-to-severe PANDAS/PANS generally requires pediatric specialists, and ideally, coordinated care among treating clinicians who may be in different care settings. For patients with mild or moderate cases, weekly therapy with Cognitive Behavioral Therapy (CBT), or outpatient daily therapy may be prescribed, but due to pediatric behavioral health workforce shortages in California, both may be difficult to access. For patients with more severe cases, space in inpatient day programs or hospitalizations, where treatment may last from one week to months, may be difficult to obtain due to California's shortage of pediatric psychiatric care clinicians and inpatient and treatment beds.
Independent Medical Review (IMR). CHBRP reviewed the state's IMR determinations and found 29 related to coverage of treatment for PANDAS, PANs, and autoimmune encephalitis. All determinations were specific to coverage of intravenous immunoglobulin (IVIg). A total of 15 IMRs overturned the decision of the health plan for enrollees requesting coverage for IVIg, based on the refractory nature of the patient's condition and sufficient evidence showing lack of improvement following first-line therapies. The health plans' decisions were upheld in 14 instances where enrollees requested coverage of IVIg either due to insufficient medical evidence and/or lack of clinical evidence supporting the patient's diagnosis and therefore medical necessity for the treatment. CHBRP found five determinations specific to the diagnosis of PANDAS and PANS. None of the medical reviews were for coverage requests of diagnostic tests or services recommended by any of the guidelines used by CHBRP for this analysis.
CHBRP notes that this bill requires coverage of PANDAS and PANS to adhere to treatment recommendations in clinical practice guidelines and evidence-based standards; the guidelines developed by the aforementioned groups are consensus guidelines. Evidence-based guidelines make statements that are informed by a systematic review of the evidence and an assessment of the benefits and harms of alternative options. Consensus guidelines are developed by an independent panel of experts with experience in the condition(s), usually multidisciplinary, convened to review the research literature in an evidence-based manner for the purpose of advancing the understanding of an issue, procedure or method. The key difference between the development of the two types of guidelines appears to be that when the evidence is of high quality, some guideline panels rely on the evidence review to guide their recommendations and the process is evidence-based. However, when the evidence is very limited and hence of low quality or very low quality, some guideline panels rely primarily on clinical experience and the process is consensus-based.
CHBRP found clinical practice guidelines from three different organizations; all recognize the syndromes' range of severity (mild, moderate, severe) and recommend similar, but not perfectly aligned, treatments.
- CHBRP analysis. CHBRP reviewed this bill and states the following in its analysis:
- Impact on expenditures. This bill increases total net annual expenditures by total net annual $2,990,000 or total net annual 0.0020% for enrollees with Department of Managed Health Care (DMHC)-regulated plans (including DMHC-regulated Medi-Cal) and California Department of Insurance (CDI)-regulated policies. Premiums for enrollees in individual plans purchased through Covered California would increase by a total of $69,000 in annual expenditures.
- Medi-Cal. For this analysis, CHBRP has included potential impacts on Medi-Cal beneficiaries. In addition to the expected increase of $1.47 million in premiums, CHBRP is estimating for the 8.8 million Medi-Cal beneficiaries enrolled in DMHC-regulated plans (a figure that represents a 0.005% increase in premiums), it seems reasonable to assume that a population proportional increase of $370,000 would occur for the 2.0 million beneficiaries enrolled in county organized health systems (COHS) managed care.
- CalPERS. For enrollees associated with CalPERS in DMHC-regulated plans, premiums would increase by 0.001% ($0.01 per member per month, or $83,000 total increase in expenditures).
- Medical effectiveness. CHBRP analyzed the strength of evidence for the effectiveness of antibiotics, psychotropic medications, cognitive behavioral therapy, plasma exchange, IVIg and other immunomodulating medications addressed by this bill, specifically, for children affected by PANDAS/PANS. Overall, the evidence is insufficient or inconclusive that any of these treatments are effective at reducing prominent symptoms, such as OCD symptoms, tics, or eating restrictions, for pediatric patients with PANDAS/PANS. The body of research on PANDAS and PANS is small (number of studies and sample sizes of available studies) compared with many other diseases and conditions. Additional studies involving controlled clinical trials, larger sample sizes, and clear eligibility criteria are necessary to determine which treatments are effective for children with PANDAS/PANS. More specifically, CHBRP found insufficient evidence on the effectiveness of CBT, psychotropics, Non-steroidal anti-inflammatory drugs, corticosteroids, plasma exchange, rituximab, mycophenolate mofetil, and vitamin D in reducing or eliminating the prominent symptoms associated with PANDAS/PANS. CHBRP found inconclusive evidence on the effectiveness of antibiotics and IVIg in reducing or eliminating the prominent symptoms associated with PANDAS/PANS. Each of the medications reviewed for this analysis is associated with a variety of side effects and harms.
- Other states. There are 10 states, including Arkansas, Delaware, Illinois, Indiana, Kansas, Maryland, Massachusetts, Minnesota, New Hampshire, and Rhode Island, that mandate at least temporary coverage of treatment for PANDAS and PANS. Arkansas mandates health plans cover the off-label use of drug treatment to treat PANS and PANDAS, but allows for cost sharing and prior authorization requirements. Delaware, Illinois, Indiana, and Maryland mandate coverage but only specify that IVIg must be covered. Massachusetts also only specifies IVIg must be covered, and sets up an advisory council on PANDAS and PANS. Kansas, New Hampshire, and Rhode Island allow for temporary coverage of treatment for PANDAS and PANS until December 31, 2023; July 1, 2024; and December 31, 2025, respectively. Minnesota's law is most similar to this bill, describing the same set of treatments that may be recommended by a health care professional for PANDAS and PANS. This year, 12 states in addition to California (Arkansas, Connecticut, Georgia, Illinois, Maine, Massachusetts, Missouri, New York, Oregon, Rhode Island, Texas, and West Virginia) have introduced legislation this year related to PANDAS and PANS.
- Impact on expenditures. This bill increases total net annual expenditures by total net annual $2,990,000 or total net annual 0.0020% for enrollees with Department of Managed Health Care (DMHC)-regulated plans (including DMHC-regulated Medi-Cal) and California Department of Insurance (CDI)-regulated policies. Premiums for enrollees in individual plans purchased through Covered California would increase by a total of $69,000 in annual expenditures.
According to the Author
Despite published PANDAS/PANS treatment guidelines that established the standard of care in 2017, insurers have continued to adhere to their own policy statements forbidding authorization of immune-focused treatments like IVIg. As a result, treatments are denied routinely without real consideration. When a prescriber or family appeals, insurers typically uphold their denial, claiming "lack of medical necessity," or "treatment is experimental." Reviewers working for insurers are often nurses or pharmacists, not physicians, and even when an insurer engages the service of a physician to determine authorization, the physician reviewer generally lacks experience in this complex, uncommon, and devastating disorder. A typical delay in receiving IVIg due to insurance denials is measured in months, if not years. Many families give up. Meanwhile, most PANS/PANDAS sufferers cannot attend school or require intensive academic accommodations such as home hospital school. They may be hospitalized medically or psychiatrically, resulting in more cost and unnecessary suffering. They may accumulate permanent neurological damage. Their parents are often unable to work and may require state unemployment or family medical leave benefits. The author states children lucky enough to have parents with financial resources to pay out of pocket, or the savvy and persistence necessary to battle the protracted appeals process, recover well with appropriate treatment. Families who lack these resources endure financial ruin, possible child abuse allegations, police "wellness checks" that go awry, and even successful suicides. According to the author, this last sad fact has led to the establishment of the POND Brain Bank at Georgetown University, where the brains of three deceased young PANDAS/PANS patients are now contributing to scientific knowledge. Ten states have passed legislation similar to this bill since 2017, including two thus far in 2023. Without legislation, insurers have shown no willingness to grant timely and medically indicated treatment to PANS/PANDAS children. As a result, the author concludes that families continue to suffer unnecessarily and the state continues to incur costs related to special education and parental loss of employment and productivity.
Arguments in Support
PANDAS Physicians Network (PPN) is non-profit organization that maintains the industry standard PPN Guidelines for Diagnostics and Therapeutics, fosters continuous education and communication within the multi-disciplinary medical community and sponsors research for developing diagnostic tests, treatment protocols, and ultimately a cure for PANS and PANDAS. With PANS/PANDAS, an infection triggers a misdirected immune response causing inflammation in the brain. Psychiatric and neurologic symptoms manifest due to the inflammation. The hallmark trait of PANS/PANDAS is the abrupt and severe onset of OCD and/or severe eating restrictions. These primary symptoms are accompanied by other emotional and behavioral changes, frequent urination, tics, motor abnormalities and/or handwriting changes. PANS and PANDAS are treatable. Early intervention and treatment are keys to easing suffering, significantly improving mental health, shortening the duration of the illness, and laying the foundation for a long-term full recovery. Lack of treatment may lead to ongoing, worsening psychological distress, school and family disruption, psychiatric hospitalization, dramatic weight loss resulting in the need for a feeding tube or intravenous hydration, and/or an evolution of the illness into a chronic state. In severe cases, PANS/PANDAS children have lost their lives to suicide. This is preventable.
Arguments in Opposition
The California Association of Health Plans, the Association of California Life and Health Insurance Companies, and America's Health Insurance Plans write that state mandates increase costs of coverage, especially for families who buy coverage without subsidies, small business owners who cannot or do not wish to self-insure, and California taxpayers who foot the bill for the state's share of those mandates. Health plans compete for business based on innovative benefit designs that increase access to care, improve quality, and contain costs. The opposition states mandate will increase costs and limit flexibility for employers. Faced with higher costs, employers must make difficult decisions about whether to absorb premium increases or seek alternative coverage options.
FISCAL COMMENTS
According to the Assembly Appropriations Committee,
- CDI estimates costs of $7,000 for 0.1 position in fiscal year (FY) 2023-24 (Insurance Fund).
- DMHC estimates it will need to add three full- time equivalents, and the total cost of this bill will be approximately:
- $157,000 in FY 2023-24;
- $990,000 in FY 2024-25; and,
- $1,014,000 in FY 2025-26 and annually thereafter (Managed Care Fund (MCF)).
DMHC notes generally, and depending on final enrollment data, a $1 million dollar increase to the MCF could result in a 2-cent increase per enrollee on assessments to full-service health plans and a 1-cent increase per enrollee to specialized health plans. To the extent this bill and others result in an additional assessment on health plans, consumers could face increased premiums as a result of this and other bills mandating coverage.
- CHBRP estimates annual premiums for enrollees in individual plans purchased through Covered California would increase by a total of $69,000, a portion of which is paid by the state (General Fund, federal funds).
- CHBRP estimates an increase of $1.47 million in premiums for enrollees in Medi-Cal managed care and $370,000 for those in Medi-Cal COHS managed care (General Fund and federal funds).
- For enrollees associated with CalPERS in DMHC-regulated plans, CHBRP estimates premiums would increase by $83,000 (these costs are borne by enrollees and state and other government entities).
VOTES
ASM HEALTH: 11-0-4
YES: Wood, Waldron, Aguiar-Curry, Boerner, Wendy Carrillo, Maienschein, McCarty, Rodriguez, Santiago, Villapudua, Weber
ABS, ABST OR NV: Arambula, Flora, Vince Fong, Joe Patterson
ASM APPROPRIATIONS: 12-1-3
YES: Holden, Bryan, Calderon, Wendy Carrillo, Mike Fong, Hart, Lowenthal, Mathis, Papan, Pellerin, Weber, Ortega
NO: Dixon
ABS, ABST OR NV: Megan Dahle, Robert Rivas, Sanchez
UPDATED
VERSION: March 16, 2023
CONSULTANT: Kristene Mapile / HEALTH / (916) 319-2097 FN: 0000746
Date of Hearing: May 10, 2023
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Chris Holden, Chair
ABPCA Bill Id:AB 907
Author:(Lowenthal) – As Amended Ver:March 16, 2023
Policy Committee: | Health | Vote: | 11 - 0 |
|
| ||
|
|
Urgency: No State Mandated Local Program: Yes Reimbursable: No
SUMMARY:
This bill requires a health care service plan (health plan) contract or health insurance policy to provide coverage for the prophylaxis, diagnosis, and treatment of Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS) and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), and prohibits this coverage from being subject to a copayment, deductible, or other cost sharing that is greater than that applied to other benefits.
FISCAL EFFECT:
- The California Department of Insurance estimates costs of $7,000 for 0.1 position in fiscal year (FY) 2023-24 (Insurance Fund).
- The Department of Managed Health Care (DMHC) estimates it will need to add three full- time equivalents, and the total cost of this bill will be approximately:
- $157,000 in FY 2023-24.
- $990,000 in FY 2024-25.
- $1,014,000 in FY 2025-26 and annually thereafter (Managed Care Fund (MCF)).
DMHC notes generally, and depending on final enrollment data, a $1 million dollar increase to the MCF could result in a 2-cent increase per enrollee on assessments to full-service health plans and a 1-cent increase per enrollee to specialized health plans. To the extent this bill and others result in an additional assessment on health plans, consumers could face increased premiums as a result of this and other bills mandating coverage.
- The California Health Benefits Review Program (CHBRP) estimates annual premiums for enrollees in individual plans purchased through Covered California would increase by a total of $69,000, a portion of which is paid by the state (General Fund, federal funds).
- CHBRP estimates an increase of $1.47 million in premiums for enrollees in Medi-Cal managed care and $370,000 for those in Medi-Cal county organized health systems (COHS) managed care (General Fund and federal funds).
- For enrollees associated with CalPERS in DMHC-regulated plans, CHBRP estimates premiums would increase by $83,000 (these costs are borne by enrollees and state and other government entities).
COMMENTS:
This bill is sponsored by California Coalition for PANS/PANDAS Advocacy. According to the author:
Despite published PANDAS/PANS treatment guidelines that established the standard of care in 2017, insurers have continued to adhere to their own policy statements forbidding authorization of immune-focused treatments like Intravenous Immunoglobulin (IVIg). As a result, treatments are denied routinely without real consideration. When a prescriber or family appeals, insurers typically uphold their denial, claiming “lack of medical necessity,” or “treatment is experimental.” Reviewers working for insurers are often nurses or pharmacists, not physicians, and even when an insurer engages the service of a physician to determine authorization, the physician reviewer generally lacks experience in this complex, uncommon, and devastating disorder. A typical delay in receiving IVIg due to insurance denials is measured in months, if not years. Many families give up.
Meanwhile, most PANS/PANDAS sufferers cannot attend school or require intensive academic accommodations such as home hospital school. They may be hospitalized medically or psychiatrically, resulting in more cost and unnecessary suffering. They may accumulate permanent neurological damage. Their parents are often unable to work and may require state unemployment or family medical leave benefits. Children lucky enough to have parents with financial resources to pay out of pocket, or the savvy and persistence necessary to battle the protracted appeals process, recover well with appropriate treatment. Families who lack these resources endure financial ruin, possible child abuse allegations, police “wellness checks” that go awry, and even successful suicides. This last sad fact has led to the establishment of the POND Brain Bank at Georgetown University, where the brains of three deceased young PANDAS/PANS patients are now contributing to scientific knowledge.
Ten states have passed legislation similar to AB 907 since 2017, including two thus far in 2023. Without legislation, insurers have shown no willingness to grant timely and medically indicated treatment to PANS/PANDAS children. As a result, families continue to suffer unnecessarily and the state continues to incur costs related to special education and parental loss of employment and productivity.
Analysis Prepared by: Allegra Kim / APPR. / (916) 319-2081
Date of Hearing: April 25, 2023
ASSEMBLY COMMITTEE ON HEALTH
Jim Wood, Chair
ABPCA Bill Id:AB 907
Author:(Lowenthal) – As Amended Ver:March 16, 2023
SUBJECT: Coverage for PANDAS and PANS.
SUMMARY: Requires a health care service plan (health plan) contract or health insurance policy to provide coverage for the prophylaxis, diagnosis, and treatment of Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS) and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) that is prescribed or ordered by a provider. Prohibits coverage for PANDAS and PANS from being subject to a copayment, coinsurance, deductible, or other cost sharing that is greater than that applied to other benefits. Prohibits a plan or insurer from denying or delaying coverage for PANDAS or PANS therapies because the enrollee or insured previously received treatment for PANDAS or PANS or was diagnosed with or received treatment for the condition under a different diagnostic name. Specifically, this bill:
- Requires a health plan contract or insurance policy, issued, amended, or renewed on or after January 1, 2024, to provide coverage for the prophylaxis, diagnosis, and treatment of PANDAS and PANS that is prescribed or ordered by a provider. Includes coverage of antibiotics, medication, and behavioral therapies to manage neuropsychiatric symptoms, immunomodulating medicines, plasma exchange, and intravenous immunoglobulin (IVIg) therapy.
- Prohibits coverage from being subject to a copayment, coinsurance, deductible, or other cost sharing that is greater than that applied to other benefits provided by the contract or policy.
- Specifies any required authorization for PANDAS and PANS prophylaxis, diagnosis, or treatment to be provided in a timely manner that is appropriate for the severity of an enrollee or insured’s condition.
- Prohibits a health plan or insurer from denying or delaying coverage for PANDAS or PANS therapies because the enrollee or insured previously received treatment, including the same or similar treatment, for PANDAS or PANS, or because the enrollee or insured was diagnosed with or received treatment for their condition under a different diagnostic name, including autoimmune encephalopathy.
- Prohibits a health plan or insurer from limiting coverage of immunomodulating therapies for PANDAS or PANS in a manner that is inconsistent with the treatment recommendations pursuant to 6) below, and from requiring a trial of therapies that treat only neuropsychiatric symptoms before authorizing coverage of immunomodulating therapies pursuant to this bill.
- Requires coverage for PANDAS and PANS to adhere to the treatment recommendations developed by a consortium of medical professionals convened to research, identify, and publish clinical practice guidelines and evidence-based standards for the diagnosis and treatment of those disorders.
- Requires PANDAS and PANS, for billing and diagnostic purposes, to be coded as autoimmune encephalitis until the American Medical Association and the federal Centers for Medicare and Medicaid Services create and assign a specific code or codes for PANDAS and PANS. Authorizes PANDAS and PANS, after the creation of that code or codes, to be coded as autoimmune encephalitis, PANDAS, or PANS. Allows, PANDAS or PANS, if known by a different common name in the future, to be coded under that name and makes the provisions of this bill apply to that disorder or syndrome.
- Exempts a specialized health care service plan contract or insurance policy that does not cover an essential health benefit (EHB), as defined, or a Medicare supplement policy.
EXISTING LAW:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 and the California Department of Insurance (CDI) to regulate health insurers. [Health and Safety Code (HSC) §1340, et seq., and Insurance Code (INS) §106, et seq.]
- Establishes as California's EHBs benchmark under the Patient Protection and Affordable Care Act (ACA), the Kaiser Small Group Health Maintenance Organization, existing California health insurance mandates, and the 10 ACA mandated benefits, including prescription drug coverage. [HSC §1367.005 and INS §10112.27]
- Prohibits, with respect to an individual or group health plan contract or health insurance policy that covers EHBs, the copayment, coinsurance, or any other form of cost sharing for a covered outpatient prescription drug for an individual prescription for a supply of up to 30 days from exceeding $250; for a product with an actuarial value at or equivalent to a Bronze level, limits cost sharing to not more than $500 for a supply of up to 30 days; and for a high deductible health plan the $250 or $500 limits apply only after an enrollee’s deductible is met. [HSC §1342.73 and INS §10123.1932]
- Defines “basic health care services” as all of the following:
- Physician services, including consultation and referral;
- Hospital inpatient services and ambulatory care services;
- Diagnostic laboratory and therapeutic radiologic services;
- Home health services;
- Preventive health services;
- Emergency health care services, including ambulance and ambulance transport services and out-of-area coverage. Basic health care services includes ambulance and ambulance transport services provided through the 911 emergency response system; and,
- Hospice care, as specified. [HSC §1345]
- Requires the criteria or guidelines used by health plans and insurers, or any entities with which plans or insurers contract for utilization review or utilization management functions, to determine whether to authorize, modify, or deny health care services to:
- Be developed with involvement from actively practicing health care providers;
- Be consistent with sound clinical principles and processes;
- Be evaluated, and updated if necessary, at least annually;
- If used as the basis of a decision to modify, delay, or deny services in a specified case under review, be disclosed to the provider and the enrollee or insured in that specified case; and,
- Be available to the public upon request. [HSC §1363.5 and INS §10123.135]
- Requires reviews, for purposes of Independent Medical Review (IMR), to determine whether the disputed health care service was medically necessary based on the specific medical needs of the enrollee or insured and any of the following:
- Peer-reviewed scientific and medical evidence regarding the effectiveness of the disputed service;
- Nationally recognized professional standards;
- Expert opinion;
- Generally accepted standards of medical practice; or,
- Treatments that are likely to provide a benefit to a patient for conditions for which other treatments are not clinically efficacious. [HSC §1374.33 and INS §10169.3]
- Requires every disability insurer that covers hospital, medical, or surgical benefits and health plan to provide an external, IMR to examine the insurer’s or plan’s coverage decisions regarding experimental or investigational therapies for an individual with a life-threatening or seriously debilitating condition, as specified. [HSC §1370.4 and INS §10145.3]
FISCAL EFFECT: Unknown. This bill has not yet been analyzed by a fiscal committee.
COMMENTS:
- PURPOSE OF THIS BILL. According to the author, despite published PANDAS/PANS treatment guidelines that established the standard of care in 2017, insurers have continued to adhere to their own policy statements forbidding authorization of immune-focused treatments like IVIg. As a result, treatments are denied routinely without real consideration. When a prescriber or family appeals, insurers typically uphold their denial, claiming “lack of medical necessity,” or “treatment is experimental.” Reviewers working for insurers are often nurses or pharmacists, not physicians, and even when an insurer engages the service of a physician to determine authorization, the physician reviewer generally lacks experience in this complex, uncommon, and devastating disorder. A typical delay in receiving IVIg due to insurance denials is measured in months, if not years. Many families give up. Meanwhile, most PANS/PANDAS sufferers cannot attend school or require intensive academic accommodations such as home hospital school. They may be hospitalized medically or psychiatrically, resulting in more cost and unnecessary suffering. They may accumulate permanent neurological damage. Their parents are often unable to work and may require state unemployment or family medical leave benefits. The author states children lucky enough to have parents with financial resources to pay out of pocket, or the savvy and persistence necessary to battle the protracted appeals process, recover well with appropriate treatment. Families who lack these resources endure financial ruin, possible child abuse allegations, police “wellness checks” that go awry, and even successful suicides. According to the author, this last sad fact has led to the establishment of the POND Brain Bank at Georgetown University, where the brains of three deceased young PANDAS/PANS patients are now contributing to scientific knowledge. Ten states have passed legislation similar to this bill since 2017, including two thus far in 2023. Without legislation, insurers have shown no willingness to grant timely and medically indicated treatment to PANS/PANDAS children. As a result, the author concludes that families continue to suffer unnecessarily and the state continues to incur costs related to special education and parental loss of employment and productivity.
- BACKGROUND. According to the California Health Benefits Review Program (CHBRP), PANDAS/PANS are terms used to describe a subset of children with symptoms that include a sudden onset of a collection of neuropsychiatric symptoms co-occurring with obsessive-compulsive disorder (OCD) and/or tic disorders usually following an infection. PANDAS, currently classified as a subset of PANS, is hypothesized by some to be triggered by an autoimmune response to Group A Streptococcal (Strep) bacteria (which cause Strep throat or soft tissue infections). More specifically, some research hypothesizes that the body’s immune system may produce antibodies (known as cross-reactive antibodies) that create a dysfunctional autoimmune response following a Group A Strep infection, which may result in a range of conditions, including rheumatic fever which affects the heart valves. These cross-reactive antibodies may occur in the brain, where the autoimmune response is thought to result in sudden onset of neuropsychiatric symptoms such as OCD, tic disorders, and other psychiatric symptoms that also present in children diagnosed with PANDAS. However, findings from other studies run counter to this hypothesis. Two prospective, blinded case-control studies have shown no observable temporal relationship between Group A Strep infection and the clinical exacerbations (i.e., worsening or increase in symptoms) associated with patients who met published diagnostic criteria for PANDAS. PANS is hypothesized to be triggered by causes other than Group A Streptococcus infection. Much remains unknown about PANDAS and PANS and controversy remains regarding whether PANDAS differs enough from pediatric OCD or tic disorders and other neuropsychiatric disorders to warrant a different diagnostic category. The body of research related to PANDAS and PANS is small (number of studies and sample sizes among studies) compared with many other diseases and conditions.
Prevalence. PANDAS/PANS has been primarily described in children between the ages of three and 12 years; however, the exact prevalence and age distribution of PANDAS/PANS is unknown. Because OCD is a required symptom for the diagnosis of PANDAS and PANS, it is thought their prevalence can be estimated as a subset of the prevalence of pediatric OCD. Epidemiological research estimates that 0.5% to 5% of children in the United States are affected by OCD. PANDAS/PANS is uncommon and despite the first publication on the topic occurring in 1998, it remains unfamiliar to much of the clinical community. Clinicians commonly involved in diagnosing PANDAS/PANS may include a family physician, pediatrician, pediatric nurse practitioner, pediatric neurologist, pediatric psychiatrist, neurodevelopmental pediatrician, pediatric rheumatologist, and pediatric allergist/immunologist. Despite the wide variety of clinicians listed, many are unfamiliar with the syndromes and how to diagnose or treat them. There are ~10 PANDAS/PANS clinics nationwide with two located in California (Stanford and UCLA).
Due to the lack of diagnostic laboratory or imaging tests specific to PANDAS/PANS, and the overlap of symptoms with multiple conditions, the diagnostic process for these syndromes is challenging. PANS has no specific diagnostic or billing codes; an ICD-10 code for PANDAS exists. This bill would require the use of the codes for autoimmune encephalitis until national billing codes for PANDAS/PANS diagnostic process relies primarily on a clinical diagnosis in conjunction with laboratory testing to rule out conditions with similar symptoms such as pediatric autoimmune encephalitis, other pediatric infection-triggered autoimmune neuropsychiatric disorders (e.g., childhood acute neuropsychiatric syndromes, Sydenham chorea, neuropsychiatric lupus, etc.), Tourette syndrome, pediatric OCD, Tumor Necrosis Factor Receptor Associated Periodic Syndrome, and central nervous system vasculitis. Misdiagnosis and children’s suppression of behaviors during diagnostic visits also make accurate diagnosis challenging. The clinical diagnosis focuses on a detailed medical history to define sudden onset, possible relation to recent infections, and documentation of current symptoms
Treatment. Treatment options for PANDAS/PANS depend on the physical and/or neuropsychiatric symptoms experienced by the patient. Treatments recommended by consensus guidelines will vary according to patient case severity and symptomology.
- Antibiotics: Penicillin, azithromycin, or other types of antibiotics may be prescribed to eliminate a bacterial infection such as Streptococcus A.
- Nonsteroidal Anti-inflammatory Drugs (NSAIDS): Nonsteroidal anti-inflammatory drugs, such as ibuprofen or naproxen, treat pain, fever, and reduce inflammation.
- Corticosteroids: Steroids are prescribed for their anti-inflammatory and immunosuppressive effects.
- Cognitive Behavioral Therapy (CBT): This therapy focuses on changing thinking patterns (gaining a better understanding of the behavior and motivation of others and using problem-solving skills to cope with difficult situations) and changing behavioral patterns (role playing to prepare for potentially problematic interactions with others and learning to how to calm the mind and body). It can be used to treat depression, anxiety disorders, OCD, eating disorders, and severe mental illness.
- Psychotropics: This large class of medications includes antidepressants (including selective serotonin reuptake inhibitors [SSRIs]), anti-anxiety medications (e.g., benzodiazepines), stimulants, and antipsychotics that are used to manage symptoms of depression, anxiety, attention deficit disorder, insomnia, and OCD or eating disorders.
- IVIg: This blood-plasma-derived product is Food and Drug administration (FDA)-approved to treat a handful of diseases but has seen growing demand for off-label PANS/PANDAS become available. National shortages have been documented due to plasma collection shortages and lengthy, complex manufacturing processes.
- B-cell modulator (rituximab): Rituximab is an immunoglobulin G1 monoclonal antibody used to treat rheumatoid arthritis, non-Hodgkin lymphoma, and chronic lymphocytic leukemia. Similar to IVIg, it is administered intravenously in a clinic setting.
- Therapeutic plasma exchange: This process uses a machine to remove patient plasma and separate the blood into its components. It discards the unwanted cells or plasma into a discard container and returns most of the remaining blood to the patient along with replacement fluids and a short-acting anticoagulant, usually citrate.
- Mycophenolate mofetil: An immunosuppressant drug FDA-approved for use by organ transplant patients to prevent organ rejection. It is also used to treat autoimmune diseases such as lupus, rheumatoid arthritis, and Crohn’s disease.
Barriers. Barriers for the diagnosis and treatment of PANDAS/PANS include the lack of evidence on effective treatment options. The lack of clinicians familiar with PANDAS and PANS contributes to long distance travel (and associated travel expenses) for families seeking care. PANDAS/PANS symptoms overlap with symptoms of other conditions, thus the lack of a definitive test and reliance on a differential diagnosis can lead to delayed diagnosis. Misdiagnosis, and children’s suppression of behaviors during assessments are also treatment barriers in PANDAS/PANS. Treatment for moderate-to-severe PANDAS/PANS generally requires pediatric specialists, and ideally, coordinated care among treating clinicians who may be in different care settings. For patients with mild or moderate cases, weekly therapy with CBT, or outpatient daily therapy may be prescribed, but due to pediatric behavioral health workforce shortages in California, both may be difficult to access. For patients with more severe cases, space in inpatient day programs or hospitalizations, where treatment may last from one week to months, may be difficult to obtain due to California’s shortage of pediatric psychiatric care clinicians and inpatient and treatment beds.
IMR. CHBRP reviewed the state’s IMR determinations since the implementation of the ACA in California and found 29 related to coverage of treatment for PANDAS, PANs, and autoimmune encephalitis. All determinations were specific to coverage of IVIg. A total of 15 IMRs overturned the decision of the health plan for enrollees requesting coverage for IVIg, based on the refractory nature of the patient’s condition and sufficient evidence showing lack of improvement following first-line therapies. The health plans’ decisions were upheld in 14 instances where enrollees requested coverage of IVIg either due to insufficient medical evidence and/or lack of clinical evidence supporting the patient’s diagnosis and therefore medical necessity for the treatment. CHBRP found five determinations specific to the diagnosis of PANDAS and PANS. None of the medical reviews were for coverage requests of diagnostic tests or services recommended by any of the guidelines used by CHBRP for this analysis.
CHBRP notes that this bill requires coverage of PANDAS and PANS to adhere to treatment recommendations in clinical practice guidelines and evidence-based standards; the guidelines developed by the aforementioned groups are consensus guidelines. Evidence-based guidelines make statements that are informed by a systematic review of the evidence and an assessment of the benefits and harms of alternative options. Consensus guidelines are developed by an independent panel of experts with experience in the condition(s), usually multidisciplinary, convened to review the research literature in an evidence-based manner for the purpose of advancing the understanding of an issue, procedure or method. The key difference between the development of the two types of guidelines appears to be that when the evidence is of high quality, some guideline panels rely on the evidence review to guide their recommendations and the process is evidence-based. However, when the evidence is very limited and hence of low quality or very low quality, some guideline panels rely primarily on clinical experience and the process is consensus-based.
CHBRP found clinical practice guidelines from three different organizations; all recognize the syndromes’ range of severity (mild, moderate, severe) and recommend similar, but not perfectly aligned, treatments.
- CHBRP analysis. AB 1996 (Thomson), Chapter 795, Statutes of 2002, requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996. SB 125 (Hernandez), Chapter 9, Statutes of 2015, added an impact assessment on EHBs, and legislation that impacts health insurance benefit designs, cost sharing, premiums, and other health insurance topics. CHBRP reviewed AB 907 and states the following in its analysis:
- Enrollees covered. At baseline, 100% of enrollees with health insurance that would be subject to this bill have coverage that includes diagnostic tests associated with PANDAS/PANS recommended by various guidelines for diagnosing PANDAS/PANS. At baseline, 100% of enrollees with health insurance that would be subject to this bill have coverage that includes some, but not all, treatments for PANDAS/PANS. Coverage by type of treatment varies substantially. CHBRP found that 100% of enrollees have health insurance that includes antibiotics commonly used for PANDAS/PANS and some oral prescription immunomodulatory medications including steroids and nonsteroidal anti-inflammatory medications (NSAIDs). Similarly, 100% of enrollees have health insurance that includes coverage for psychotropics used for treatment of neuropsychiatric symptoms of PANDAS/PANS, including SSRIs, benzodiazepines, and antipsychotics. One hundred percent of enrollees also have health insurance that includes coverage of behavioral health therapies used for treatment of neuropsychiatric symptoms of PANDAS/PANS, including CBT. CHBRP finds that 0% of enrollees have coverage for intravenous immunomodulating therapies, including plasma exchange, B-cell modulators (rituximab), and IVIg therapy. Insufficient evidence indicates that there is not enough evidence available to know whether or not a treatment is effective, either because there are too few studies of the treatment or because the available studies are not of high quality. It does not indicate that a treatment is not effective. Postmandate, 100% of enrollees with health insurance subject to this bill would have coverage for all diagnostic tests and treatments included under this bill.
- Impact on expenditures. This bill increases total net annual expenditures by total net annual $2,990,000 or total net annual 0.0020% for enrollees with DMHC-regulated plans (including DMHC-regulated Medi-Cal) and CDI-regulated policies. Premiums for enrollees in individual plans purchased through Covered California would increase by a total of $69,000 in annual expenditures.
- Medi-Cal. For this analysis, CHBRP has included potential impacts on Medi-Cal beneficiaries. In addition to the expected increase of $1.47 million in premiums, CHBRP is estimating for the 8.8 million Medi-Cal beneficiaries enrolled in DMHC-regulated plans (a figure that represents a 0.005% increase in premiums), it seems reasonable to assume that a population proportional increase of $370,000 would occur for the 2.0 million beneficiaries enrolled in county organized health systems (COHS) managed care.
- CalPERS. For enrollees associated with CalPERS in DMHC-regulated plans, premiums would increase by 0.001% ($0.01 per member per month, or $83,000 total increase in expenditures).
- Uninsured. Since the change in average premiums does not exceed 1% for any market segment, CHBRP would expect no measurable change in the number of uninsured persons due to the enactment of this bill.
- EHBs. This bill would not require coverage for a new state benefit mandate that appears to exceed the definition of EHBs in California.
- Medical effectiveness. CHBRP analyzed the strength of evidence for the effectiveness of antibiotics, psychotropic medications, cognitive behavioral therapy, plasma exchange, IVIg and other immunomodulating medications addressed by this bill, specifically, for children affected by PANDAS/PANS. Overall, the evidence is insufficient or inconclusive that any of these treatments are effective at reducing prominent symptoms, such as OCD symptoms, tics, or eating restrictions, for pediatric patients with PANDAS/PANS. The body of research on PANDAS and PANS is small (number of studies and sample sizes of available studies) compared with many other diseases and conditions. Additional studies involving controlled clinical trials, larger sample sizes, and clear eligibility criteria are necessary to determine which treatments are effective for children with PANDAS/PANS. More specifically, CHBRP found insufficient evidence on the effectiveness of CBT, psychotropics, NSAIDs, corticosteroids, plasma exchange, rituximab, mycophenolate mofetil, and vitamin D in reducing or eliminating the prominent symptoms associated with PANDAS/PANS. CHBRP found inconclusive evidence on the effectiveness of antibiotics and IVIg in reducing or eliminating the prominent symptoms associated with PANDAS/PANS. Each of the medications reviewed for this analysis is associated with a variety of side effects and harms.
- Utilization. CHBRP estimates that at baseline, 15,410 enrollees use diagnostic tests for PANDAS/PANS. These include various blood tests, throat cultures, and nose swabs. CHBRP estimates that for every 23 children tested for PANDAS/PANS using these diagnostic tests, one child is diagnosed with PANDAS/PANS and 22 children are not given this diagnosis. Given that 100% of enrollees already have baseline coverage, CHBRP estimates no changes in utilization for these diagnostic tests. At baseline, CHBRP estimates that 670 enrollees have a PANDAS/PANS diagnosis. Among these enrollees, average annual utilization of oral prescription medications used for the treatment and management of neuropsychiatric symptoms (including medications such as antibiotics, steroids, NSAIDs, and psychotropics) is 17.8 prescriptions, each with a 30-day supply. At baseline, annual utilization of CBT is 20 visits per year. Given that 100% of enrollees already have baseline coverage for these medications and behavioral health therapies such as CBT, CHBRP estimated no changes in utilization of these specific medications and CBT services postmandate. CHBRP estimates that IVIg, rituximab, and plasma exchange have extremely limited use at baseline. CHBRP estimates that average annual utilization of IVIg among all enrollees with PANDAS/PANS would increase to 0.7 infusion therapy sessions per year. This results in an estimated 90 enrollees with moderate or severe PANDAS/PANS utilizing IVIg at least once per year, with greater expected utilization among those with severe PANDAS/PANS. CHBRP estimates that average annual utilization of rituximab would increase to 0.1 infusion therapy sessions. This results in an estimated 22 enrollees with severe PANDAS/PANS utilizing an estimated average of three rituximab infusions per year. CHBRP estimated no change in the use of plasma exchange services given their low availability and the lack of evidence of their effectiveness in PANDAS/PANS.
- Public health. In the first year postmandate, the public health impact of this bill is unknown due to insufficient and inconclusive evidence regarding the effectiveness of treatments for PANDAS/PANS.
- Long-term impacts. Utilization of diagnostic tests and treatments for PANDAS/PANS is expected to be similar in the long term as utilization in the first 12 months postmandate. However, should evidence about the effectiveness of new diagnostic tests or treatments such as IVIg or rituximab become more conclusive, for example, via more evidence from larger randomized controlled clinical trials, more physicians may prescribe these treatments. Cost impacts are expected to also be similar to those projected in the first 12 months postmandate.
- Other states. There are 10 states, including Arkansas, Delaware, Illinois, Indiana, Kansas, Maryland, Massachusetts, Minnesota, New Hampshire, and Rhode Island, that mandate at least temporary coverage of treatment for PANDAS and PANS. Arkansas mandates health plans cover the off-label use of drug treatment to treat PANS and PANDAS, but allows for cost sharing and prior authorization requirements. Delaware, Illinois, Indiana, and Maryland mandate coverage but only specify that IVIg must be covered. Massachusetts also only specifies IVIg must be covered, and sets up an advisory council on PANDAS and PANS. Kansas, New Hampshire, and Rhode Island allow for temporary coverage of treatment for PANDAS and PANS until December 31, 2023; July 1, 2024; and December 31, 2025, respectively. Minnesota’s law is most similar to this bill, describing the same set of treatments that may be recommended by a health care professional for PANDAS and PANS. This year, 12 states in addition to California (Arkansas, Connecticut, Georgia, Illinois, Maine, Massachusetts, Missouri, New York, Oregon, Rhode Island, Texas, and West Virginia) have introduced legislation this year related to PANDAS and PANS. Arkansas’ and Illinois’ legislation would amend their existing laws to specify conditions under which IVIg and other treatment coverage must be provided. Rhode Island’s legislation would have extended the sunset for coverage for treatment but was held for further study. Massachusetts’ bill would order a study to be conducted related to PANDAS and PANs in conjunction with its PANS advisory council. Georgia’s legislation would establish a three-year pilot program to provide coverage for the diagnosis and treatment of PANDAS and PANS, beginning in 2025. The Missouri and Oregon bills would specify coverage for IVIG treatments, and Maine’s bill would provide coverage for the similar treatments as those mandated in this bill. New York and Connecticut’s legislation would mandate coverage for unspecified treatment of PANS. Texas’ bill would establish PANS advisory council. West Virginia’s legislation mandates coverage for IVIG for PANDAS and PANS and other autoimmune encephalopathies only if prior authorization is obtained by showing all other treatments have been exhausted.
- CHBRP analysis. AB 1996 (Thomson), Chapter 795, Statutes of 2002, requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996. SB 125 (Hernandez), Chapter 9, Statutes of 2015, added an impact assessment on EHBs, and legislation that impacts health insurance benefit designs, cost sharing, premiums, and other health insurance topics. CHBRP reviewed AB 907 and states the following in its analysis:
- SUPPORT. PANDAS Physicians Network (PPN) is non-profit organization that maintains the industry standard PPN Guidelines for Diagnostics and Therapeutics, fosters continuous education and communication within the multi-disciplinary medical community and sponsors research for developing diagnostic tests, treatment protocols, and ultimately a cure for PANS and PANDAS. With PANS/PANDAS, an infection triggers a misdirected immune response causing inflammation in the brain. Psychiatric and neurologic symptoms manifest due to the inflammation. The hallmark trait of PANS/PANDAS is the abrupt and severe onset of OCD and/or severe eating restrictions. These primary symptoms are accompanied by other emotional and behavioral changes, frequent urination, tics, motor abnormalities and/or handwriting changes. PANS and PANDAS are treatable. Early intervention and treatment are keys to easing suffering, significantly improving mental health, shortening the duration of the illness, and laying the foundation for a long-term full recovery. Lack of treatment may lead to ongoing, worsening psychological distress, school and family disruption, psychiatric hospitalization, dramatic weight loss resulting in the need for a feeding tube or intravenous hydration, and/or an evolution of the illness into a chronic state. In severe cases, PANS/PANDAS children have lost their lives to suicide. This is preventable.
The Alliance to Solve PANS and Immune Related Encephalopathies write this bill will significantly improve the health and well-being of patients with PANS and ease the financial and emotional burdens of their families. PANS is characterized by the abrupt and dramatic onset of obsessivecompulsive symptoms, restricted intake of food or fluids (sometimes to the point of starvation or dehydration), anxiety, depression and suicidality, emotional lability, personality changes, sensory hypersensitivity, cognitive deficits and physical symptoms, such as arthralgias, urinary dysfunction, and severe insomnia. As its name implies, PANS affects children, primarily those aged four through nine years. Insurance coverage for PANS PANDAS would address this concern through efforts to educate providers and raise awareness about PANS/PANDAS. Without such measures, many families must travel long distances to access treatment at great emotional and monetary expense. For others, the inability to travel due to financial circumstances or the severity of a child's illness postpones or precludes therapeutic interventions entirely.
- OPPOSITION. The California Association of Health Plans, the Association of California Life and Health Insurance Companies, and America’s Health Insurance Plans write that state mandates increase costs of coverage, especially for families who buy coverage without subsidies, small business owners who cannot or do not wish to self-insure, and California taxpayers who foot the bill for the state’s share of those mandates. Health plans compete for business based on innovative benefit designs that increase access to care, improve quality, and contain costs. All ACA-compliant plans provide a robust package of EHBs in the large group, small business, and individual markets (both on and off the Exchange). In the individual market, the ACA sought to preserve the balance between comprehensive coverage and affordability by requiring states to bear the cost for new mandates that exceed the EHB package. The Centers for Medicaid and Medicare Services recently affirmed that states are still responsible for defraying the cost of new mandates. The opposition states mandate will increase costs and limit flexibility for employers. Faced with higher costs, employers must make difficult decisions about whether to absorb premium increases or seek alternative coverage options.
- RELATED LEGISLATION.
- AB 620 (Connelly) expands existing law requiring every health care plan contract or disability insurance to cover the testing and treatment of phenylketonuria, to also cover the testing and treatment of other digestive and inherited metabolic disorders, on or after January 1, 2024. AB 620 is pending in Assembly Health Committee.
- AB 874 (Weber) requires a health plan, health insurance policy, other health coverage carrier, or pharmacy benefit manager that administers pharmacy benefits to apply any amounts paid by the enrollee, insured, or another source pursuant to a discount, repayment, product voucher, or other reduction to the enrollee’s or insured’s out-of-pocket expenses toward the enrollee’s or insured’s overall contribution to any out-of-pocket maximum, deductible, copayment, coinsurance, or applicable cost-sharing requirement under the enrollee’s or insured’s health plan, health insurance policy, or other health care coverage. AB 874 is pending in Assembly Health Committee.
- POLICY COMMENTS. As this bill moves forward, the author may wish to consider a delayed implementation for health plan coverage to address changes to Covered California’s standard benefit design, if any.
REGISTERED SUPPORT / OPPOSITION:
Support
California Coalition for PANS/PANDAS Advocacy (sponsor)
Alliance to Solve PANS & Immune-Related Encephalopathies
Autoimmune Registry INC.
California Federation of Teachers AFL-CIO
California Health Coalition Advocacy
California Life Sciences
California School Nurses Organization
California Teamsters Public Affairs Council
Expand, the European Immuno-neuropsychiatric Association
Moleculera Labs
PANDAS Physicians Network, a Division of The Foundation for Brain Science and Immunology
Stand Up Sacramento County
The Alex Manfull Fund
The Pace Foundation
Numerous individuals
Opposition
America's Health Insurance Plans (AHIP)
Association of California Life & Health Insurance Companies
California Association of Health Plans
Analysis Prepared by: Kristene Mapile / HEALTH / (916) 319-2097
Discussed in Hearing
Assembly Floor
Senate Floor
Senate Standing Committee on Health
Assembly Standing Committee on Health
Bill Author
Bill Co-Author(s):